BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhou J, Sun HC, Wang Z, Cong WM, Wang JH, Zeng MS, Yang JM, Bie P, Liu LX, Wen TF, Han GH, Wang MQ, Liu RB, Lu LG, Ren ZG, Chen MS, Zeng ZC, Liang P, Liang CH, Chen M, Yan FH, Wang WP, Ji Y, Cheng WW, Dai CL, Jia WD, Li YM, Li YX, Liang J, Liu TS, Lv GY, Mao YL, Ren WX, Shi HC, Wang WT, Wang XY, Xing BC, Xu JM, Yang JY, Yang YF, Ye SL, Yin ZY, Zhang BH, Zhang SJ, Zhou WP, Zhu JY, Liu R, Shi YH, Xiao YS, Dai Z, Teng GJ, Cai JQ, Wang WL, Dong JH, Li Q, Shen F, Qin SK, Fan J. Guidelines for Diagnosis and Treatment of Primary Liver Cancer in China (2017 Edition). Liver Cancer. 2018;7:235-260. [PMID: 30319983 DOI: 10.1159/000488035] [Cited by in Crossref: 186] [Cited by in F6Publishing: 196] [Article Influence: 46.5] [Reference Citation Analysis]
Number Citing Articles
1 Zhang W, Qi S, Zhuo J, Wen S, Fang C. Concordance Study in Hepatectomy Recommendations Between Watson for Oncology and Clinical Practice for Patients with Hepatocellular Carcinoma in China. World J Surg 2020;44:1945-53. [PMID: 32020325 DOI: 10.1007/s00268-020-05401-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
2 Wang D, Bai T, Chen G, Liu J, Chen M, Zhao Y, Luo T, Chen J, Li L, Zhang C, Li H. Upregulation of long non-coding RNA FOXP4-AS1 and its regulatory network in hepatocellular carcinoma. Onco Targets Ther 2019;12:7025-38. [PMID: 31695417 DOI: 10.2147/OTT.S220923] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
3 Dai J, Zhao J, Du Y, Zhuang L, McNeil EB, Chongsuvivatwong V. Adherence to Hepatocellular Carcinoma Surveillance and Perceived Barriers Among High-Risk Chronic Liver Disease Patients in Yunnan, China. Cancer Manag Res 2020;12:6209-20. [PMID: 32884337 DOI: 10.2147/CMAR.S259195] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Liu C, Wu J, Chang Z. Trends and Age-Period-Cohort Effects on the Prevalence, Incidence and Mortality of Hepatocellular Carcinoma from 2008 to 2017 in Tianjin, China. Int J Environ Res Public Health 2021;18:6034. [PMID: 34199687 DOI: 10.3390/ijerph18116034] [Reference Citation Analysis]
5 Hendi M, Mou Y, Lv J, Zhang B, Cai X. Hepatic Arterial Infusion Chemotherapy Is a Feasible Treatment Option for Hepatocellular Carcinoma: A New Update. Gastrointest Tumors 2021;8:145-52. [PMID: 34722467 DOI: 10.1159/000516405] [Reference Citation Analysis]
6 Fu Z, Li X, Zhong J, Chen X, Cao K, Ding N, Liu L, Zhang X, Zhai J, Qu Z. Lenvatinib in combination with transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma (uHCC): a retrospective controlled study. Hepatol Int 2021;15:663-75. [PMID: 33877527 DOI: 10.1007/s12072-021-10184-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 12.0] [Reference Citation Analysis]
7 Xu L, Li L, Wang P, Zhang M, Zhang Y, Hao X, Yan L, Li B, Wen T, Xu M. Novel Prognostic Nomograms for Hepatocellular Carcinoma Patients with Microvascular Invasion: Experience from a Single Center. Gut Liver 2019;13:669-82. [PMID: 30970430 DOI: 10.5009/gnl18489] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
8 Feng H, Yang C, Xu F, Zhao Y, Jin T, Wei Z, Wang D, Dai C. Therapeutic efficacy of microwave coagulation versus liver resection for hepatocellular carcinoma within the Milan criteria: A propensity score matching analysis. Eur J Surg Oncol 2021:S0748-7983(21)00725-3. [PMID: 34509336 DOI: 10.1016/j.ejso.2021.08.035] [Reference Citation Analysis]
9 Zhang Y, Shu Z, Ye Q, Chen J, Zhong J, Jiang H, Wu C, Yu T, Pang P, Ma T, Lin C. Preoperative Prediction of Microvascular Invasion in Hepatocellular Carcinoma via Multi-Parametric MRI Radiomics. Front Oncol 2021;11:633596. [PMID: 33747956 DOI: 10.3389/fonc.2021.633596] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Zhou JM, Zhou CY, Chen XP, Zhang ZW. Anatomic resection improved the long-term outcome of hepatocellular carcinoma patients with microvascular invasion: A prospective cohort study. World J Gastrointest Oncol 2021; 13(12): 2190-2202 [DOI: 10.4251/wjgo.v13.i12.2190] [Reference Citation Analysis]
11 Cheng M, Zhu Z, Ye S, Chen J, Dong X, Gao G. Clinical Value of Plasma Secreted Frizzled-Related Protein 4 in the Chronic Hepatitis B Virus Infection: A Cross-sectional Study. Hepat Mon 2021;21. [DOI: 10.5812/hepatmon.116525] [Reference Citation Analysis]
12 Zhang D, Wei Q, Wu GG, Zhang XY, Lu WW, Lv WZ, Liao JT, Cui XW, Ni XJ, Dietrich CF. Preoperative Prediction of Microvascular Invasion in Patients With Hepatocellular Carcinoma Based on Radiomics Nomogram Using Contrast-Enhanced Ultrasound. Front Oncol 2021;11:709339. [PMID: 34557410 DOI: 10.3389/fonc.2021.709339] [Reference Citation Analysis]
13 Hack SP, Spahn J, Chen M, Cheng A, Kaseb A, Kudo M, Lee HC, Yopp A, Chow P, Qin S. IMbrave 050: a Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation. Future Oncology 2020;16:975-89. [DOI: 10.2217/fon-2020-0162] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 15.5] [Reference Citation Analysis]
14 Dai J, Zhao J, Du Y, Zhuang L, Ma Y, Chongsuvivatwong V. Clinico-Psychosocial Factors Predicting Hepatocellular Carcinoma Related Knowledge Among Patients with Chronic Liver Disease. J Cancer Educ 2020;35:937-45. [PMID: 31090039 DOI: 10.1007/s13187-019-01545-y] [Reference Citation Analysis]
15 Pan Y, Mei J, Chen J, Zhang D, Wang J, Wang X, Yi M, Zhou Z, Zhang Y, Chen M, Guo R, Xu L. Comparison Between Portal Vein Perfusion Chemotherapy and Neoadjuvant Hepatic Arterial Infusion Chemotherapy for Resectable Intermediate to Advanced Stage Hepatocellular Carcinoma. Ann Surg Oncol 2021. [PMID: 34637058 DOI: 10.1245/s10434-021-10903-4] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Kong Y, Jing Y, Sun H, Zhou S, M.a B. The Diagnostic Value of Contrast-Enhanced Ultrasound and Enhanced CT Combined with Tumor Markers AFP and CA199 in Liver Cancer. Journal of Healthcare Engineering 2022;2022:1-10. [DOI: 10.1155/2022/5074571] [Reference Citation Analysis]
17 Li S, Huang J, Yang F, Zeng H, Tong Y, Li K. High expression of PARD3 predicts poor prognosis in hepatocellular carcinoma. Sci Rep 2021;11:11078. [PMID: 34040099 DOI: 10.1038/s41598-021-90507-w] [Reference Citation Analysis]
18 You Y, Long Y, Yan R, Luo L, Zhang M, Li L, Zeng Q, Li K, Zheng R, Xu E. Improving Ablation Safety for Hepatocellular Carcinoma Proximal to the Hilar Bile Ducts by Ultrasound-MR Fusion Imaging: A Preliminary Comparative Study. Front Oncol 2021;11:570312. [PMID: 33732639 DOI: 10.3389/fonc.2021.570312] [Reference Citation Analysis]
19 Wu D, Yang Y, Chen J, Cai H, Duan Y, Sun D. Three Different Ways of Treating Primary Hepatocellular Carcinoma at an Early Stage: A Prospective Comparative Study. Gastroenterol Res Pract 2020;2020:7802498. [PMID: 32508913 DOI: 10.1155/2020/7802498] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
20 Arellano RS. What's New in Percutaneous Ablative Strategies for Hepatocellular Carcinoma and Colorectal Hepatic Metastases? 2020 Update. Curr Oncol Rep 2020;22:105. [PMID: 32725433 DOI: 10.1007/s11912-020-00967-y] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
21 Wang HH, Liu ZC, Zhang G, Li LH, Li L, Meng QB, Wang PJ, Shen DQ, Dang XW. Clinical characteristics and outcome of primary hepatic neuroendocrine tumors after comprehensive therapy. World J Gastrointest Oncol 2020; 12(9): 1031-1043 [PMID: 33005296 DOI: 10.4251/wjgo.v12.i9.1031] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
22 Xu Y, Wei FX. A retrospective study of enteral nutrition on immune and inflammatory factors after liver cancer surgery. Medicine (Baltimore) 2021;100:e27718. [PMID: 34871264 DOI: 10.1097/MD.0000000000027718] [Reference Citation Analysis]
23 Li Z, Jiao D, Han X, Si G, Li Y, Liu J, Xu Y, Zheng B, Zhang X. Transcatheter arterial chemoembolization combined with simultaneous DynaCT-guided microwave ablation in the treatment of small hepatocellular carcinoma. Cancer Imaging 2020;20:13. [PMID: 32000862 DOI: 10.1186/s40644-020-0294-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
24 Huang C, Zhu XD, Shen YH, Wu D, Ji Y, Ge NL, Chen LL, Tan CJ, Zhou J, Fan J, Sun HC. Organ specific responses to first-line lenvatinib plus anti-PD-1 antibodies in patients with unresectable hepatocellular carcinoma: a retrospective analysis. Biomark Res 2021;9:19. [PMID: 33743822 DOI: 10.1186/s40364-021-00274-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
25 Xiao L, Zeng F, Deng G. Commentary on: Nomograms based on inflammatory biomarkers for predicting tumor grade and microvascular invasion in stage I/II hepatocellular carcinoma. Biosci Rep 2019;39:BSR20190683. [PMID: 31652457 DOI: 10.1042/BSR20190683] [Reference Citation Analysis]
26 Cao X, Cao Z, Ou C, Zhang L, Chen Y, Li Y, Zhu B, Shu H. Combination of serum paraoxonase/arylesterase 1 and antithrombin-III is a promising non-invasion biomarker for discrimination of AFP-negative HCC versus liver cirrhosis patients. Clin Res Hepatol Gastroenterol 2021;45:101583. [PMID: 33756265 DOI: 10.1016/j.clinre.2020.11.013] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Yi Y, Yu MC, Fu PY, Liu G, Zhou PY, Guan RY, Zhou C, Sun BY, Qiu SJ. MNS1 promotes hepatocarcinogenesis and metastasis via activating PI3K/AKT by translocating β-catenin and predicts poor prognosis. Liver Int 2021;41:1409-20. [PMID: 33506565 DOI: 10.1111/liv.14803] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Lu L, Zheng P, Wu Z, Chen X. Hepatic Resection Versus Transarterial Chemoembolization for Intermediate-Stage Hepatocellular Carcinoma: A Cohort Study. Front Oncol 2021;11:618937. [PMID: 34778022 DOI: 10.3389/fonc.2021.618937] [Reference Citation Analysis]
29 Chen CP. Role of External Beam Radiotherapy in Hepatocellular Carcinoma. Clin Liver Dis 2020;24:701-17. [PMID: 33012454 DOI: 10.1016/j.cld.2020.07.006] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
30 Zhuang Y, Yuan BY, Chen GW, Zhao XM, Hu Y, Zhu WC, Zeng ZC, Chen YX. Association Between Circulating Lymphocyte Populations and Outcome After Stereotactic Body Radiation Therapy in Patients With Hepatocellular Carcinoma. Front Oncol 2019;9:896. [PMID: 31552194 DOI: 10.3389/fonc.2019.00896] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
31 Foerster F, Galle PR. Comparison of the current international guidelines on the management of HCC. J Hep Reports. 2019;1:114-119. [PMID: 32039359 DOI: 10.1016/j.jhepr.2019.04.005] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 5.7] [Reference Citation Analysis]
32 Shi F, Zhou Z, Huang X, Liu Q, Lin A. Is anatomical resection necessary for early hepatocellular carcinoma? A single institution retrospective experience. Future Oncology 2019;15:2041-51. [DOI: 10.2217/fon-2019-0117] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
33 Chen J, Chen C, Lin Y, Su Y, Yu X, Jiang Y, Chen Z, Ke S, Lin S, Chen L, Zhang Z, Zhang T. Downregulation of SUMO2 inhibits hepatocellular carcinoma cell proliferation, migration and invasion. FEBS Open Bio 2021;11:1771-84. [PMID: 33989451 DOI: 10.1002/2211-5463.13173] [Reference Citation Analysis]
34 Fan Z, Yang G, Zhang W, Liu Q, Liu G, Liu P, Xu L, Wang J, Yan Z, Han H, Liu R, Shu M. Hypoxia blocks ferroptosis of hepatocellular carcinoma via suppression of METTL14 triggered YTHDF2-dependent silencing of SLC7A11. J Cell Mol Med 2021;25:10197-212. [PMID: 34609072 DOI: 10.1111/jcmm.16957] [Reference Citation Analysis]
35 Zhang L, Li Y, Dai Y, Wang D, Wang X, Cao Y, Liu W, Tao Z. Glycolysis-related gene expression profiling serves as a novel prognosis risk predictor for human hepatocellular carcinoma. Sci Rep 2021;11:18875. [PMID: 34556750 DOI: 10.1038/s41598-021-98381-2] [Reference Citation Analysis]
36 Xiao N, Li XL, Zhu XD, Huang C, Shen YH, Zhou J, Fan J, Sun HC. Increase of Portal Vein Pressure Gradient After Hepatectomy Predicts Post-operative Liver Dysfunction. Surg Innov 2021;:15533506211018620. [PMID: 33993786 DOI: 10.1177/15533506211018620] [Reference Citation Analysis]
37 Jia F, Wu B, Yan R, Li L, Wang K, Han D. Prediction Model for Intermediate-Stage Hepatocellular Carcinoma Response to Transarterial Chemoembolization. J Magn Reson Imaging 2020;52:1657-67. [PMID: 32424881 DOI: 10.1002/jmri.27189] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
38 Bai Y, Tong W, Xie F, Zhu L, Wu H, Shi R, Wang L, Yang L, Liu Z, Miao F, Zhao Q, Zhang Y. DNA methylation biomarkers for diagnosis of primary liver cancer and distinguishing hepatocellular carcinoma from intrahepatic cholangiocarcinoma. Aging (Albany NY) 2021;13:17592-606. [PMID: 34237708 DOI: 10.18632/aging.203249] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
39 Shi JY, Wang X, Ding GY, Dong Z, Han J, Guan Z, Ma LJ, Zheng Y, Zhang L, Yu GZ, Wang XY, Ding ZB, Ke AW, Yang H, Wang L, Ai L, Cao Y, Zhou J, Fan J, Liu X, Gao Q. Exploring prognostic indicators in the pathological images of hepatocellular carcinoma based on deep learning. Gut 2021;70:951-61. [PMID: 32998878 DOI: 10.1136/gutjnl-2020-320930] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 19.0] [Reference Citation Analysis]
40 Koh DM, Ba-Ssalamah A, Brancatelli G, Fananapazir G, Fiel MI, Goshima S, Ju SH, Kartalis N, Kudo M, Lee JM, Murakami T, Seidensticker M, Sirlin CB, Tan CH, Wang J, Yoon JH, Zeng M, Zhou J, Taouli B. Consensus report from the 9th International Forum for Liver Magnetic Resonance Imaging: applications of gadoxetic acid-enhanced imaging. Eur Radiol 2021;31:5615-28. [PMID: 33523304 DOI: 10.1007/s00330-020-07637-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
41 Zheng BH, Liu LZ, Zhang ZZ, Shi JY, Dong LQ, Tian LY, Ding ZB, Ji Y, Rao SX, Zhou J, Fan J, Wang XY, Gao Q. Radiomics score: a potential prognostic imaging feature for postoperative survival of solitary HCC patients. BMC Cancer. 2018;18:1148. [PMID: 30463529 DOI: 10.1186/s12885-018-5024-z] [Cited by in Crossref: 52] [Cited by in F6Publishing: 52] [Article Influence: 13.0] [Reference Citation Analysis]
42 Jiang J, Chu G, Chen G, Liao H, Yu L, Yu H, Liu J, Hu Z. A case report of rare intraperitoneal cholesteatoma diagnosed and treated through multidisciplinary collaboration. Clin Case Rep 2020;8:1965-70. [PMID: 33088530 DOI: 10.1002/ccr3.3075] [Reference Citation Analysis]
43 Li Z, Hao D, Jiao D, Zhang W, Han X. Transcatheter Arterial Chemoembolization Combined with Simultaneous Cone-beam Computed Tomography-guided Microwave Ablation in the Treatment of Small Hepatocellular Carcinoma: Clinical Experiences From 50 Procedures. Acad Radiol 2021;28 Suppl 1:S64-70. [PMID: 33060007 DOI: 10.1016/j.acra.2020.08.036] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
44 Wang S, Liu D, Wei H, Hua Y, Shi G, Qiao J. The hsa_circRNA_102049 mediates the sorafenib sensitivity of hepatocellular carcinoma cells by regulating Reelin gene expression. Bioengineered 2022;13:2272-84. [PMID: 35034536 DOI: 10.1080/21655979.2021.2024332] [Reference Citation Analysis]
45 Sun Y, Bai H, Xia W, Wang D, Zhou B, Zhao X, Yang G, Xu L, Zhang W, Liu P, Xu J, Meng S, Liu R, Gao X. Predicting the Outcome of Transcatheter Arterial Embolization Therapy for Unresectable Hepatocellular Carcinoma Based on Radiomics of Preoperative Multiparameter MRI. J Magn Reson Imaging 2020;52:1083-90. [PMID: 32233054 DOI: 10.1002/jmri.27143] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
46 Zhong BY, Wang WS, Zhang S, Zhu HD, Zhang L, Shen J, Zhu XL, Teng GJ, Ni CF. Re-evaluating Transarterial Chemoembolization Failure/Refractoriness: A Survey by Chinese College of Interventionalists. J Clin Transl Hepatol 2021;9:521-7. [PMID: 34447681 DOI: 10.14218/JCTH.2021.00049] [Reference Citation Analysis]
47 Yin Y, Cheng JW, Chen FY, Chen XX, Zhang X, Huang A, Guo DZ, Wang YP, Cao Y, Fan J, Zhou J, Yang XR. A novel preoperative predictive model of 90-day mortality after liver resection for huge hepatocellular carcinoma. Ann Transl Med 2021;9:774. [PMID: 34268387 DOI: 10.21037/atm-20-7842] [Reference Citation Analysis]
48 Minami Y, Kudo M. Adjuvant therapy after radical surgery for hepatocellular carcinoma: still an unmet need. Hepatobiliary Surg Nutr 2019;8:414-6. [PMID: 31489318 DOI: 10.21037/hbsn.2019.04.05] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
49 Sun HC, Zhu XD, Zhou J, Gao Q, Shi YH, Ding ZB, Huang C, Qiu SJ, Ren N, Shi GM, Sun J, Ye QH, Huang XW, Yang XR, Fan J. Adjuvant apatinib treatment after resection of hepatocellular carcinoma with portal vein tumor thrombosis: a phase II trial. Ann Transl Med 2020;8:1301. [PMID: 33209881 DOI: 10.21037/atm-20-6181] [Reference Citation Analysis]
50 Xu M, Ma T, Shi S, Xing J, Xi Y. Development and Validation of a Mutational Burden-Associated LncRNA Signature for Improving the Clinical Outcome of Hepatocellular Carcinoma. Life (Basel) 2021;11:1312. [PMID: 34947843 DOI: 10.3390/life11121312] [Reference Citation Analysis]
51 Liu K, Ding Y, Wang Y, Zhao Q, Yan L, Xie J, Liu Y, Xie Q, Cai W, Bao S, Wang H. Combination of IL-34 and AFP improves the diagnostic value during the development of HBV related hepatocellular carcinoma. Clin Exp Med. [DOI: 10.1007/s10238-022-00810-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
52 Zeng J, Zeng J, Huang Y, Liu J, Zeng J. The effect of adjuvant transarterial chemoembolization for hepatocellular carcinoma after liver resection based on risk stratification. Hepatobiliary & Pancreatic Diseases International 2022. [DOI: 10.1016/j.hbpd.2022.07.007] [Reference Citation Analysis]
53 Cao Y, Zhang H. Recent advances in nano material-based application of liver neoplasms. Smart Materials in Medicine 2021;2:114-23. [DOI: 10.1016/j.smaim.2021.03.001] [Reference Citation Analysis]
54 Tsai F, Liu X, Chen C, Li T, Chiou J, Chuang P, Ko C, Lin T, Liao C, Huang S, Liang W, Lin Y. Chinese herbal medicine therapy and the risk of overall mortality for patients with liver cancer who underwent surgical resection in Taiwan. Complementary Therapies in Medicine 2019;47:102213. [DOI: 10.1016/j.ctim.2019.102213] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
55 Xia Y, Tang W, Qian X, Li X, Cheng F, Wang K, Zhang F, Zhang C, Li D, Song J, Zhang H, Zhao J, Yao A, Wu X, Wu C, Ji G, Liu X, Zhu F, Qin L, Xiao X, Deng Z, Kong X, Li S, Yu Y, Xi W, Deng W, Qi C, Liu H, Pu L, Wang P, Wang X. Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial. J Immunother Cancer 2022;10:e004656. [DOI: 10.1136/jitc-2022-004656] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
56 Lee J, Jeong MI, Kim HR, Park H, Moon WK, Kim B. Plant Extracts as Possible Agents for Sequela of Cancer Therapies and Cachexia. Antioxidants (Basel) 2020;9:E836. [PMID: 32906727 DOI: 10.3390/antiox9090836] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
57 Fan J, Wang L, Chen M, Zhang J, Li J, Song F, Gu A, Yin D, Yi Y. Analysis of the expression and prognosis for leukocyte immunoglobulin-like receptor subfamily B in human liver cancer. World J Surg Oncol 2022;20:92. [PMID: 35321724 DOI: 10.1186/s12957-022-02562-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
58 Li C, Chen K, Liu X, Liu HT, Liang XM, Liang GL, Tang ST, Huo RR, Ma L, Xiang BB, Zhong JH, Li LQ. Analysis of Clinicopathological Characteristics and Prognosis of Young Patients with Hepatocellular Carcinoma after Hepatectomy. J Clin Transl Hepatol 2020;8:285-91. [PMID: 33083251 DOI: 10.14218/JCTH.2020.00021] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
59 Zeng J, Zeng J, Wu Q, Lin K, Zeng J, Guo P, Zhou W, Liu J. Novel inflammation-based prognostic nomograms for individualized prediction in hepatocellular carcinoma after radical resection. Ann Transl Med 2020;8:1061. [PMID: 33145280 DOI: 10.21037/atm-20-1919] [Reference Citation Analysis]
60 Huang HF, Jin PP, Yang HJ, Zhang CJ, Zhang X, Wang JS, Yu JJ, Zhang B, Zhang Y, Hu QD. Primary Hepatic Neuroendocrine Tumor Mimicking Ruptured Hepatocellular Carcinoma with AFP Elevation: A Case Report and Literature Review. Onco Targets Ther 2020;13:975-9. [PMID: 32099400 DOI: 10.2147/OTT.S236728] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
61 Lu SD, Li L, Liang XM, Chen W, Chen FL, Fan LL, Ahir BK, Zhang WG, Zhong JH. Updates and advancements in the management of hepatocellular carcinoma patients after hepatectomy. Expert Rev Gastroenterol Hepatol 2019;13:1077-88. [PMID: 31648568 DOI: 10.1080/17474124.2019.1684898] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
62 Wei CY, Chen PC, Chau GY, Lee RC, Chen PH, Huo TI, Huang YH, Su YH, Hou MC, Wu JC, Su CW. Comparison of prognosis between surgical resection and transarterial chemoembolization for patients with solitary huge hepatocellular carcinoma. Ann Transl Med 2020;8:238. [PMID: 32309385 DOI: 10.21037/atm.2019.12.157] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
63 Feng Y, Dramani Maman ST, Zhu X, Liu X, Bongolo CC, Liang C, Tu J. Clinical value and potential mechanisms of LINC00221 in hepatocellular carcinoma based on integrated analysis. Epigenomics 2021;13:299-317. [PMID: 33406920 DOI: 10.2217/epi-2020-0363] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
64 Zhu XD, Sun HC. Emerging agents and regimens for hepatocellular carcinoma. J Hematol Oncol. 2019;12:110. [PMID: 31655607 DOI: 10.1186/s13045-019-0794-6] [Cited by in Crossref: 35] [Cited by in F6Publishing: 38] [Article Influence: 11.7] [Reference Citation Analysis]
65 Mai RY, Wang YY, Bai T, Chen J, Xiang BD, Wu GB, Wu FX, Li LQ, Ye JZ. Combination Of ALBI And APRI To Predict Post-Hepatectomy Liver Failure After Liver Resection For HBV-Related HCC Patients. Cancer Manag Res. 2019;11:8799-8806. [PMID: 31632139 DOI: 10.2147/cmar.s213432] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
66 Cai M, Li B, Lin L, Huang J, An Y, Huang W, Zhou Z, Wang Y, Shuai X, Zhu K. A reduction and pH dual-sensitive nanodrug for targeted theranostics in hepatocellular carcinoma. Biomater Sci 2020;8:3485-99. [PMID: 32432234 DOI: 10.1039/d0bm00295j] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
67 Yuan G, Li J, Yu S, Chen X, He S. Letter to the Editor: Predicting Postoperative Liver Dysfunction Based on Blood Derived MicroRNA Signatures. Hepatology 2019;70:1080-1. [PMID: 31034633 DOI: 10.1002/hep.30689] [Reference Citation Analysis]
68 Sun YF, Wu L, Liu SP, Jiang MM, Hu B, Zhou KQ, Guo W, Xu Y, Zhong Y, Zhou XR, Zhang ZF, Liu G, Liu S, Shi YH, Ji Y, Du M, Li NN, Li GB, Zhao ZK, Huang XY, Xu LQ, Yu QC, Peng DH, Qiu SJ, Sun HC, Dean M, Wang XD, Chung WY, Dennison AR, Zhou J, Hou Y, Fan J, Yang XR. Dissecting spatial heterogeneity and the immune-evasion mechanism of CTCs by single-cell RNA-seq in hepatocellular carcinoma. Nat Commun 2021;12:4091. [PMID: 34215748 DOI: 10.1038/s41467-021-24386-0] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
69 Li Z, Jiao D, Wang C, Li J, Liu Z, Zhang W, Han X. Microwave Ablation of Small Hepatic Metastases Using MR Guidance and Monitoring: Clinical Safety and Efficacy. Cancer Manag Res 2021;13:3357-66. [PMID: 33889024 DOI: 10.2147/CMAR.S301856] [Reference Citation Analysis]
70 Xu W, Li R, Liu F. Novel Prognostic Nomograms for Predicting Early and Late Recurrence of Hepatocellular Carcinoma After Curative Hepatectomy. Cancer Manag Res. 2020;12:1693-1712. [PMID: 32214844 DOI: 10.2147/cmar.s241959] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
71 Zheng W, Shen GL, Xu KY, Yin QQ, Hui TC, Zhou ZW, Xu CA, Wang SH, Wu WH, Shi LF, Pan HY. Lnc524369 promotes hepatocellular carcinoma progression and predicts poor survival by activating YWHAZ-RAF1 signaling. World J Gastrointest Oncol 2022; 14(1): 253-264 [DOI: 10.4251/wjgo.v14.i1.253] [Reference Citation Analysis]
72 Tian Y, Wang J, Tian G, Li B, Chen M, Sun X. Long Non-Coding RNA MAFG-AS1 as a Potential Biomarker for Hepatocellular Carcinoma: Linkage with Tumor Features, Markers, Liver Functions, and Survival Profile. Front Surg 2022;9:848831. [DOI: 10.3389/fsurg.2022.848831] [Reference Citation Analysis]
73 Wen Z, Feng Y, Hu Y, Lian L, Huang H, Guo L, Chen S, Yang Q, Zhang M, Wan L, Xu K, Degejirifu, Yan X. Multiwalled carbon nanotubes co-delivering sorafenib and epidermal growth factor receptor siRNA enhanced tumor-suppressing effect on liver cancer. Aging (Albany NY) 2021;13:1872-82. [PMID: 33440348 DOI: 10.18632/aging.103905] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
74 Liu Y, Xie K, Li J, Wang Z, Zeng Y, Wu H. Successful management of the hepatocellular carcinoma with inferior vena cava tumor thrombus: A case report. Medicine (Baltimore) 2021;100:e26081. [PMID: 34032742 DOI: 10.1097/MD.0000000000026081] [Reference Citation Analysis]
75 Chen Z, Lu X, Koral K. The clinical application of camrelizumab on advanced hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol 2020;14:1017-24. [PMID: 32762583 DOI: 10.1080/17474124.2020.1807939] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
76 Chen M, Wang D, Liu J, Zhou Z, Ding Z, Liu L, Su D, Li H. MicroRNA-587 Functions as a Tumor Suppressor in Hepatocellular Carcinoma by Targeting Ribosomal Protein SA. Biomed Res Int 2020;2020:3280530. [PMID: 32964027 DOI: 10.1155/2020/3280530] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
77 Chen CP. Role of Radiotherapy in the Treatment of Hepatocellular Carcinoma. J Clin Transl Hepatol. 2019;7:183-190. [PMID: 31293919 DOI: 10.14218/jcth.2018.00060] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
78 Zhou G, Zeng Y, Luo Y, Guo S, Bao L, Zhang Q. Urine miR-93-5p is a promising biomarker for early detection of HBV-related hepatocellular carcinoma. Eur J Surg Oncol 2021:S0748-7983(21)00579-5. [PMID: 34175168 DOI: 10.1016/j.ejso.2021.06.015] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
79 Chen L, Zeng F, Yao L, Fang T, Liao M, Long J, Xiao L, Deng G. Nomogram based on inflammatory indices for differentiating intrahepatic cholangiocarcinoma from hepatocellular carcinoma. Cancer Med 2020;9:1451-61. [PMID: 31903730 DOI: 10.1002/cam4.2823] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
80 Zhou C, Zhang X, Peng Y, Zhou K, Hu J, Yu L, Chen F, Qiu S, Zhou J, Fan J, Zhang L, Wang Z. Surgical Resection plus Radiofrequency Ablation versus Radical Surgery for Hepatocellular Carcinoma: A Propensity Score Matching Analysis. J Cancer 2019;10:3933-40. [PMID: 31417637 DOI: 10.7150/jca.29501] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
81 Zhang XF, Lv Y. Liver Transplant for Patients with Hepato-cellular Carcinoma and Child-Pugh C Liver Function Should Be Mentioned in Guidelines. Liver Cancer 2019;8:522-3. [PMID: 31799209 DOI: 10.1159/000497459] [Reference Citation Analysis]
82 Shen J, Tang L, Zhang X, Peng W, Wen T, Li C, Yang J, Liu G. A Novel Index in Hepatocellular Carcinoma Patients After Curative Hepatectomy: Albumin to Gamma-Glutamyltransferase Ratio (AGR). Front Oncol 2019;9:817. [PMID: 31612101 DOI: 10.3389/fonc.2019.00817] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
83 Zhu XD, Li KS, Sun HC. Adjuvant therapies after curative treatments for hepatocellular carcinoma: Current status and prospects. Genes Dis 2020;7:359-69. [PMID: 32884990 DOI: 10.1016/j.gendis.2020.02.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
84 Lu JC, Zeng HY, Sun QM, Meng QN, Huang XY, Zhang PF, Yang X, Peng R, Gao C, Wei CY, Shen YH, Cai JB, Dong RZ, Shi YH, Sun HC, Shi YG, Zhou J, Fan J, Ke AW, Yang LX, Shi GM. Distinct PD-L1/PD1 Profiles and Clinical Implications in Intrahepatic Cholangiocarcinoma Patients with Different Risk Factors. Theranostics 2019;9:4678-87. [PMID: 31367249 DOI: 10.7150/thno.36276] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 10.7] [Reference Citation Analysis]
85 Zheng L, Fang S, Wu F, Chen W, Chen M, Weng Q, Wu X, Song J, Zhao Z, Ji J. Efficacy and Safety of TACE Combined With Sorafenib Plus Immune Checkpoint Inhibitors for the Treatment of Intermediate and Advanced TACE-Refractory Hepatocellular Carcinoma: A Retrospective Study. Front Mol Biosci 2020;7:609322. [PMID: 33521054 DOI: 10.3389/fmolb.2020.609322] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
86 Rim CH. Differences in radiotherapy application according to regional disease characteristics of hepatocellular carcinoma. J Liver Cancer 2021;21:113-23. [DOI: 10.17998/jlc.2021.05.26] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
87 Llovet JM, Villanueva A, Marrero JA, Schwartz M, Meyer T, Galle PR, Lencioni R, Greten TF, Kudo M, Mandrekar SJ, Zhu AX, Finn RS, Roberts LR; AASLD Panel of Experts on Trial Design in HCC. Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference. Hepatology 2021;73 Suppl 1:158-91. [PMID: 32430997 DOI: 10.1002/hep.31327] [Cited by in Crossref: 66] [Cited by in F6Publishing: 46] [Article Influence: 66.0] [Reference Citation Analysis]
88 Yang X, Hu Y, Yang K, Wang D, Lin J, Long J, Xie F, Mao J, Bian J, Guan M, Pan J, Huo L, Hu K, Yang X, Mao Y, Sang X, Zhang J, Wang X, Zhang H, Zhao H. Cell-free DNA copy number variations predict efficacy of immune checkpoint inhibitor-based therapy in hepatobiliary cancers. J Immunother Cancer 2021;9:e001942. [PMID: 33972389 DOI: 10.1136/jitc-2020-001942] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
89 Zhu GQ, Liu WR, Tang Z, Qu WF, Fang Y, Jiang XF, Song SS, Wang H, Tao CY, Zhou PY, Huang R, Gao J, Sun HX, Ding ZB, Peng YF, Dai Z, Zhou J, Fan J, Shi YH. Serial circulating tumor DNA to predict early recurrence in patients with hepatocellular carcinoma: a prospective study. Mol Oncol 2021. [PMID: 34543520 DOI: 10.1002/1878-0261.13105] [Reference Citation Analysis]
90 Xia D, Wang Q, Bai W, Wang E, Wang Z, Mu W, Sun J, Huang M, Yin G, Li H, Zhao H, Zhang C, Li J, Wu J, Zhu X, Yang S, Pan X, Li J, Li Z, Xu G, Shi H, Zhang H, Zhang Y, Ding R, Yu H, Zheng L, Yang X, Wang G, You N, Feng L, Zhang S, Huang W, Xu T, Fan W, Li X, Yang X, Zhou W, Wang W, Li X, Wang Z, Luo B, Niu J, Yuan J, Lv Y, Li K, Guo W, Yin Z, Fan D, Xia J, Han G; China HCC-TACE Study Group. Optimal time point of response assessment for predicting survival is associated with tumor burden in hepatocellular carcinoma receiving repeated transarterial chemoembolization. Eur Radiol 2022. [PMID: 35381853 DOI: 10.1007/s00330-022-08716-4] [Reference Citation Analysis]
91 Su TS, Li LQ, Meng WW, Wang YD, Chen YT, Li JX, Du YQ, Qu S, Zhao C, Huang DJ, Liang SX, Li LQ. Long-Term Survival Analysis of Transarterial Chemoembolization Plus Radiotherapy vs. Radiotherapy for Hepatocellular Carcinoma With Macroscopic Vascular Invasion. Front Oncol 2020;10:1205. [PMID: 32850352 DOI: 10.3389/fonc.2020.01205] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
92 Iaria M, Bianchi G, Fazio F, Ardito F, Perri P, Pontarolo N, Conci S, Donadon M, Zanello M, Lai Q, Famularo S, Molfino S, Sciannamea I, Fumagalli L, Germani P, Floridi A, Ferrari C, Zimmitti G, Troci A, Zago M, Ferraro V, Cipriani F, Patauner S, La Barba G, Romano M, Zanus G, Ercolani G, Frena A, Aldrighetti L, Memeo R, Pinotti E, Crespi M, Hilal MA, Griseri G, Tarchi P, Chiarelli M, Antonucci A, Baiocchi GL, Romano F, Rossi M, Jovine E, Torzilli G, Ruzzenente A, Maestri M, Grazi GL, Giuliante F, Ferrero A, Dalla Valle R; HE.RC.O.LE.S. GROUP. The largest western experience on salvage hepatectomy for recurrent hepatocellular carcinoma: propensity score-matched analysis on behalf of He.RC.O.Le.Study Group. HPB (Oxford) 2022:S1365-182X(22)00001-6. [PMID: 35125292 DOI: 10.1016/j.hpb.2022.01.001] [Reference Citation Analysis]
93 Zeng J, Lin K, Liu H, Huang Y, Guo P, Zeng Y, Zeng J, Liu J. Prognosis Factors of Young Patients Undergoing Curative Resection for Hepatitis B Virus-Related Hepatocellular Carcinoma: A Multicenter Study. Cancer Manag Res 2020;12:6597-606. [PMID: 32848453 DOI: 10.2147/CMAR.S261368] [Reference Citation Analysis]
94 Mai R, Bai T, Luo X, Wu G. Indocyanine Green Retention Test as a Predictor of Postoperative Complications in Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma. TCRM 2022;Volume 18:761-72. [DOI: 10.2147/tcrm.s363849] [Reference Citation Analysis]
95 Chen A, Li S, Yao Z, Hu J, Cao J, Topatana W, Juengpanich S, Yu H, Shen J, Chen M. Adjuvant transarterial chemoembolization to sorafenib in unresectable hepatocellular carcinoma: A meta-analysis. J Gastroenterol Hepatol 2021;36:302-10. [PMID: 32652685 DOI: 10.1111/jgh.15180] [Reference Citation Analysis]
96 Han X, Gu YK, Li SL, Chen H, Chen MS, Cai QQ, Deng HX, Zuo MX, Huang JH. Pre-treatment serum levels of soluble programmed cell death-ligand 1 predict prognosis in patients with hepatitis B-related hepatocellular carcinoma. J Cancer Res Clin Oncol 2019;145:303-12. [PMID: 30267213 DOI: 10.1007/s00432-018-2758-6] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 6.0] [Reference Citation Analysis]
97 Liu Y, Li Y, Gao F, Zhang Q, Yang X, Zhu B, Niu S, Huang Y, Hu Y, Li W, Wang X. Comparison of Transcatheter Arterial Chemoembolization-Radiofrequency Ablation and Transcatheter Arterial Chemoembolization Alone for Advanced Hepatocellular Carcinoma with Macrovascular Invasion Using Propensity Score Analysis: A Retrospective Cohort Study. J Oncol 2020;2020:1341863. [PMID: 32884569 DOI: 10.1155/2020/1341863] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
98 Tan Y, Xie XY, Li XJ, Liu DH, Zhou LY, Zhang XE, Lin Y, Wang W, Wu SS, Liu J, Huang GL. Comparison of hepatic epithelioid angiomyolipoma and non-hepatitis B, non-hepatitis C hepatocellular carcinoma on contrast-enhanced ultrasound. Diagn Interv Imaging 2020;101:733-8. [PMID: 32331793 DOI: 10.1016/j.diii.2020.03.005] [Reference Citation Analysis]
99 Qiu Z, Shen L, Chen S, Qi H, Cao F, Xie L, Fan W. Efficacy Of Apatinib In Transcatheter Arterial Chemoembolization (TACE) Refractory Intermediate And Advanced-Stage Hepatocellular carcinoma:A Propensity Score Matching Analysis. Cancer Manag Res 2019;11:9321-30. [PMID: 31802950 DOI: 10.2147/CMAR.S223271] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
100 Ding GY, Ma JQ, Yun JP, Chen X, Ling Y, Zhang S, Shi JY, Chang YQ, Ji Y, Wang XY, Tan WM, Yuan KF, Yan B, Zhang XM, Liang F, Zhou J, Fan J, Zeng Y, Cai MY, Gao Q. Distribution and density of tertiary lymphoid structures predict clinical outcome in intrahepatic cholangiocarcinoma. J Hepatol 2021:S0168-8278(21)02178-4. [PMID: 34793865 DOI: 10.1016/j.jhep.2021.10.030] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
101 Zhou L, Chen L, Yang L, Cai L, Liu L, Zhao Y, Feng Y, Liu N, Zhao Y, Xia Y, Wei H, Chen Y. Preliminary Studies of 177Lu-Diethylenetriamine Penta-Acetic Acid-Deoxyglucose in Hepatic Tumor-Bearing Mice. Cancer Biother Radiopharm 2020;35:33-40. [PMID: 31750727 DOI: 10.1089/cbr.2019.2903] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
102 Welberry C, Macdonald I, McElveen J, Parsy-Kowalska C, Allen J, Healey G, Irving W, Murray A, Chapman C. Tumor-associated autoantibodies in combination with alpha-fetoprotein for detection of early stage hepatocellular carcinoma. PLoS One 2020;15:e0232247. [PMID: 32374744 DOI: 10.1371/journal.pone.0232247] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
103 Huang J, Tian W, Zhang L, Huang Q, Lin S, Ding Y, Liang W, Zheng S. Preoperative Prediction Power of Imaging Methods for Microvascular Invasion in Hepatocellular Carcinoma: A Systemic Review and Meta-Analysis. Front Oncol 2020;10:887. [PMID: 32676450 DOI: 10.3389/fonc.2020.00887] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
104 Ke Q, Xiang F, Xiao C, Huang Q, Liu X, Zeng Y, Wang L, Liu J. Exploring the clinical value of preoperative serum gamma-glutamyl transferase levels in the management of patients with hepatocellular carcinoma receiving postoperative adjuvant transarterial chemoembolization. BMC Cancer 2021;21:1117. [PMID: 34663242 DOI: 10.1186/s12885-021-08843-z] [Reference Citation Analysis]
105 Lyu L, Yang W, Yao J, Wang H, Zhu J, Jin A, Liu T, Wang B, Zhou J, Fan J, Yang X, Guo W. The diagnostic value of plasma exosomal hsa_circ_0070396 for hepatocellular carcinoma. Biomark Med 2021;15:359-71. [PMID: 33666515 DOI: 10.2217/bmm-2020-0476] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
106 Liu X, Luo J, Zhang L, Yang F, Peng D. SIB-IMRT combined with apatinib for unresectable hepatocellular carcinoma in patients with poor response to transarterial chemoembolization. Clin Res Hepatol Gastroenterol 2022;:101897. [PMID: 35240318 DOI: 10.1016/j.clinre.2022.101897] [Reference Citation Analysis]
107 Wang H, Liu D, Wang C, Yu S, Jin G, Wang C, Zhang B, Zhang D, Shao D. Transarterial chemoembolization (TACE) plus apatinib-combined therapy versus TACE alone in the treatment of intermediate to advanced hepatocellular carcinoma patients: a real-world study. Clin Res Hepatol Gastroenterol 2022;:101869. [PMID: 35108656 DOI: 10.1016/j.clinre.2022.101869] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
108 Qiu G, Jin Z, Chen X, Huang J. Interpretation of guidelines for the diagnosis and treatment of primary liver cancer (2019 edition) in China. Glob Health Med. 2020;2:306-311. [PMID: 33330825 DOI: 10.35772/ghm.2020.01051] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
109 Gao Q, Zhu H, Dong L, Shi W, Chen R, Song Z, Huang C, Li J, Dong X, Zhou Y, Liu Q, Ma L, Wang X, Zhou J, Liu Y, Boja E, Robles AI, Ma W, Wang P, Li Y, Ding L, Wen B, Zhang B, Rodriguez H, Gao D, Zhou H, Fan J. Integrated Proteogenomic Characterization of HBV-Related Hepatocellular Carcinoma. Cell 2019; 179: 561-577. e22. [PMID: 31585088 DOI: 10.1016/j.cell.2019.08.052] [Cited by in Crossref: 134] [Cited by in F6Publishing: 135] [Article Influence: 67.0] [Reference Citation Analysis]
110 Zhao H, Zhou A, Zhou J, Bi X, Yan S, Jin J, Wei W, Li M, Gong C, Chen Q, Luo Z, Li N, Mao R, Chen X, Chen B, Zheng R, Zhao J, Han Y, Li Z, Che X, Tang Y, Sun Y, Huang Z, Zhang Y, Wang X, Zhang Y, Lu Z, Dang X, Song T, Liu C, Yue P, Yan D, Yue A, Zhang R, Luo S, Tan J, Zhang X, Bai X, Zhang X, He M, Xie Y, Wang W, Yang P, Yang Y, Zhang Y, Li Q, Peng T, Wang Z, Chen Y, Shang C, Liang Y, Zhang B, Zhang F, Wang L, Li D, Liu B, Zhu X, Hu Q, Chen M, Xiu D, Xia F, Zhang Y, Zeng Y, Mao Y, Li X, Ba Y, Liang T, Shen F, Liu L, Cai X, Zhou J, Cai J. Chinese expert recommendations on management of hepatocellular carcinoma during COVID-19 pandemic: a nationwide multicenter survey. HPB (Oxford) 2021:S1365-182X(21)00633-X. [PMID: 34400051 DOI: 10.1016/j.hpb.2021.07.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
111 Lee MS, Ryoo BY, Hsu CH, Numata K, Stein S, Verret W, Hack SP, Spahn J, Liu B, Abdullah H, Wang Y, He AR, Lee KH;  GO30140 investigators. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study. Lancet Oncol. 2020;21:808-820. [PMID: 32502443 DOI: 10.1016/s1470-2045(20)30156-x] [Cited by in Crossref: 78] [Cited by in F6Publishing: 63] [Article Influence: 39.0] [Reference Citation Analysis]
112 Zhang XY, Ou J, Chen JY, Li WW. Predicting early hepatocellular carcinoma recurrence after resection: A comment for moving forward. J Hepatol 2019;70:567-8. [PMID: 30554930 DOI: 10.1016/j.jhep.2018.10.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
113 Li WH, Li D. Effect of electrical stimulation for chemotherapy-induced nausea and vomiting in patients with liver cancer. Medicine (Baltimore) 2019;98:e15255. [PMID: 31008963 DOI: 10.1097/MD.0000000000015255] [Reference Citation Analysis]
114 Tao Z, Ruan Y, Peng Z, Zhang K, Gao Y. Transarterial Chemoembolization Combined With Endoscopic Therapy Is Beneficial for Unresectable Hepatocellular Carcinoma With Esophagogastric Varices. Front Oncol 2021;11:783574. [PMID: 34926300 DOI: 10.3389/fonc.2021.783574] [Reference Citation Analysis]
115 Wang F, Liu H, Bai Y, Li H, Wang Z, Xu X. Performance of SPINK1 and SPINK1-based diagnostic model in detection of hepatocellular carcinoma. J Clin Lab Anal 2021;35:e24025. [PMID: 34569662 DOI: 10.1002/jcla.24025] [Reference Citation Analysis]
116 Minami Y, Morita M, Chishina H, Aoki T, Takita M, Hagiwara S, Ida H, Ueshima K, Nishida N, Kudo M. Can the Entire Ablative Hyperechoic Zone be Regarded as a Necrotic Lesion After Radiofrequency Ablation of the Liver? Ultrasound Med Biol 2021;47:2930-5. [PMID: 34266681 DOI: 10.1016/j.ultrasmedbio.2021.05.004] [Reference Citation Analysis]
117 Huang Y, Chen H, Zeng Y, Liu Z, Ma H, Liu J. Development and Validation of a Machine Learning Prognostic Model for Hepatocellular Carcinoma Recurrence After Surgical Resection. Front Oncol 2020;10:593741. [PMID: 33598425 DOI: 10.3389/fonc.2020.593741] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
118 Li J, Ling W, Chen S, Ma L, Yang L, Lu Q, Luo Y. The interreader agreement and validation of contrast-enhanced ultrasound liver imaging reporting and data system. European Journal of Radiology 2019;120:108685. [DOI: 10.1016/j.ejrad.2019.108685] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 4.7] [Reference Citation Analysis]
119 Chen LT, Martinelli E, Cheng AL, Pentheroudakis G, Qin S, Bhattacharyya GS, Ikeda M, Lim HY, Ho GF, Choo SP, Ren Z, Malhotra H, Ueno M, Ryoo BY, Kiang TC, Tai D, Vogel A, Cervantes A, Lu SN, Yen CJ, Huang YH, Chen SC, Hsu C, Shen YC, Tabernero J, Yen Y, Hsu CH, Yoshino T, Douillard JY. Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS-ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO. Ann Oncol. 2020;31:334-351. [PMID: 32067677 DOI: 10.1016/j.annonc.2019.12.001] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 8.3] [Reference Citation Analysis]
120 Wang L, Jin YX, Ji YZ, Mu Y, Zhang SC, Pan SY. Development and validation of a prediction model for microvascular invasion in hepatocellular carcinoma. World J Gastroenterol 2020; 26(14): 1647-1659 [PMID: 32327913 DOI: 10.3748/wjg.v26.i14.1647] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 19] [Article Influence: 9.0] [Reference Citation Analysis]
121 Zhou PC, Sun LQ, Shao L, Yi LZ, Li N, Fan XG. Establishment of a pattern recognition metabolomics model for the diagnosis of hepatocellular carcinoma. World J Gastroenterol 2020; 26(31): 4607-4623 [PMID: 32884220 DOI: 10.3748/wjg.v26.i31.4607] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
122 Ni J, Huang R, Zhou H, Xu X, Li Y, Cao P, Zhong K, Ge M, Chen X, Hou B, Yu M, Peng B, Li Q, Zhang P, Gao Y. Analysis of the Relationship Between the Degree of Dysbiosis in Gut Microbiota and Prognosis at Different Stages of Primary Hepatocellular Carcinoma. Front Microbiol 2019;10:1458. [PMID: 31293562 DOI: 10.3389/fmicb.2019.01458] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 7.3] [Reference Citation Analysis]
123 Li X, Wang Y, Ye X, Liang P. Locoregional Combined With Systemic Therapies for Advanced Hepatocellular Carcinoma: An Inevitable Trend of Rapid Development. Front Mol Biosci 2021;8:635243. [PMID: 33928118 DOI: 10.3389/fmolb.2021.635243] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
124 Peng R, Zhang PF, Yang X, Wei CY, Huang XY, Cai JB, Lu JC, Gao C, Sun HX, Gao Q, Bai DS, Shi GM, Ke AW, Fan J. Overexpression of RNF38 facilitates TGF-β signaling by Ubiquitinating and degrading AHNAK in hepatocellular carcinoma. J Exp Clin Cancer Res 2019;38:113. [PMID: 30836988 DOI: 10.1186/s13046-019-1113-3] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
125 Piratvisuth T, Tanwandee T, Thongsawat S, Sukeepaisarnjaroen W, Esteban JI, Bes M, Köhler B, He Y, Swiatek-de Lange M, Morgenstern D, Chan HL. Multimarker Panels for Detection of Early Stage Hepatocellular Carcinoma: A Prospective, Multicenter, Case-Control Study. Hepatol Commun 2021. [PMID: 34796691 DOI: 10.1002/hep4.1847] [Reference Citation Analysis]
126 Liu LX, Lu JC, Zeng HY, Cai JB, Zhang PF, Guo XJ, Huang XY, Dong RZ, Zhang C, Kang Q, Zou H, Zhang XY, Zhang L, Zhang XW, Ke AW, Shi GM. Mortalin stabilizes CD151-depedent tetraspanin-enriched microdomains and implicates in the progression of hepatocellular carcinoma. J Cancer 2019;10:6199-206. [PMID: 31772652 DOI: 10.7150/jca.36301] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
127 Song X, He Y, Liang H, Han M, Shao Z. INTRABEAM intraoperative radiotherapy combined with portal vein infusion chemotherapy for treating hepatocellular carcinoma with portal vein tumor thrombus. BMC Surg 2020;20:174. [PMID: 32738882 DOI: 10.1186/s12893-020-00836-2] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
128 Deng G, Yao L, Zeng F, Xiao L, Wang Z. Nomogram For Preoperative Prediction Of Microvascular Invasion Risk In Hepatocellular Carcinoma. Cancer Manag Res. 2019;11:9037-9045. [PMID: 31695495 DOI: 10.2147/cmar.s216178] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
129 Kudo M. Targeted and immune therapies for hepatocellular carcinoma: Predictions for 2019 and beyond. World J Gastroenterol 2019; 25(7): 789-807 [PMID: 30809080 DOI: 10.3748/wjg.v25.i7.789] [Cited by in CrossRef: 92] [Cited by in F6Publishing: 81] [Article Influence: 30.7] [Reference Citation Analysis]
130 Gong J, Li Y, Yu J, Wang T, Duan J, Hu A, He X, Zhu X. The predictive role of preoperative serum glutamate dehydrogenase levels in microvascular invasion and hepatocellular carcinoma prognosis following liver transplantation-a single center retrospective study. PeerJ 2021;9:e12420. [PMID: 34760395 DOI: 10.7717/peerj.12420] [Reference Citation Analysis]
131 Hu K, Yuan J, Tang B, Zhang F, Lu S, Chen R, Zhang L, Ren Z, Yin X. Albumin-bilirubin index and platelet-albumin-bilirubin index contribute to identifying survival benefit candidates in patients with hepatocellular carcinoma and Child-Pugh grade A undergoing transcatheter arterial chemoembolization with sorafenib treatment. Ann Transl Med 2021;9:237. [PMID: 33708864 DOI: 10.21037/atm-20-3118] [Reference Citation Analysis]
132 Chen RX, Gan YH, Ge NL, Chen Y, Ma M, Zhang BH, Wang YH, Ye SL, Luo JF, Ren ZG. A new prediction model for prognosis of patients with intermediate-stage HCC after conventional transarterial chemoembolization: an internally validated study. J Cancer 2019;10:6535-42. [PMID: 31777583 DOI: 10.7150/jca.34064] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
133 Ding GY, Zhu XD, Ji Y, Shi GM, Shen YH, Zhou J, Fan J, Sun HC, Huang C. Serum PON1 as a biomarker for the estimation of microvascular invasion in hepatocellular carcinoma. Ann Transl Med 2020;8:204. [PMID: 32309351 DOI: 10.21037/atm.2020.01.44] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
134 Yaseen MM, Abuharfeil NM, Darmani H. The clinical and prognostic significance of CMTM6/PD-L1 in oncology. Clin Transl Oncol 2022. [PMID: 35278198 DOI: 10.1007/s12094-022-02811-0] [Reference Citation Analysis]
135 Gu Y, Zheng F, Zhang Y, Qiao S. Novel Nomogram Based on Inflammatory Markers for the Preoperative Prediction of Microvascular Invasion in Solitary Primary Hepatocellular Carcinoma. CMAR 2022;Volume 14:895-907. [DOI: 10.2147/cmar.s346976] [Reference Citation Analysis]
136 Zeng J, Zeng J, Liu J, Zeng J. Development of pre and post-operative nomograms to predict individual survival for ideal liver resection candidates with hepatocellular carcinoma. Liver Int 2021. [PMID: 34416088 DOI: 10.1111/liv.15042] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
137 Cai M, Huang W, Huang J, Shi W, Guo Y, Liang L, Zhou J, Lin L, Cao B, Chen Y, Zhou J, Zhu K. Transarterial Chemoembolization Combined With Lenvatinib Plus PD-1 Inhibitor for Advanced Hepatocellular Carcinoma: A Retrospective Cohort Study. Front Immunol 2022;13:848387. [PMID: 35300325 DOI: 10.3389/fimmu.2022.848387] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
138 Wang CY, Li S. Clinical characteristics and prognosis of 2887 patients with hepatocellular carcinoma: A single center 14 years experience from China. Medicine (Baltimore) 2019;98:e14070. [PMID: 30681563 DOI: 10.1097/MD.0000000000014070] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 4.3] [Reference Citation Analysis]
139 Zheng L, Fang S, Wu F, Chen W, Chen M, Weng Q, Wu X, Song J, Zhao Z, Ji J. Efficacy and Safety of TACE Combined With Sorafenib Plus Immune Checkpoint Inhibitors for the Treatment of Intermediate and Advanced TACE-Refractory Hepatocellular Carcinoma: A Retrospective Study. Front Mol Biosci 2020;7:609322. [PMID: 33521054 DOI: 10.3389/fmolb.2020.609322] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
140 Chen J, Zhu J, Wang G, Groopman JD, Kensler TW. Qidong: a crucible for studies on liver cancer etiology and prevention. Cancer Biol Med 2019;16:24-37. [PMID: 31119044 DOI: 10.20892/j.issn.2095-3941.2018.0394] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
141 Guo J, Wang S, Han Y, Jia Z, Wang R. Effects of transarterial chemoembolization on the immunological function of patients with hepatocellular carcinoma. Oncol Lett 2021;22:554. [PMID: 34084221 DOI: 10.3892/ol.2021.12815] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
142 Park S, Yoon WS, Rim CH. Indications of external radiotherapy for hepatocellular carcinoma from updated clinical guidelines: Diverse global viewpoints. World J Gastroenterol 2020; 26(4): 393-403 [PMID: 32063688 DOI: 10.3748/wjg.v26.i4.393] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 16] [Article Influence: 11.0] [Reference Citation Analysis]
143 Feng LH, Sun HC, Zhu XD, Liu XF, Zhang SZ, Li XL, Li Y, Tang ZY. Prognostic nomograms and risk classifications of outcomes in very early-stage hepatocellular carcinoma patients after hepatectomy. Eur J Surg Oncol 2021;47:681-9. [PMID: 33189491 DOI: 10.1016/j.ejso.2020.10.039] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
144 Asadian S, Piryaei A, Gheibi N, Aziz Kalantari B, Reza Davarpanah M, Azad M, Kapustina V, Alikhani M, Moghbeli Nejad S, Keshavarz Alikhani H, Mohamadi M, Shpichka A, Timashev P, Hassan M, Vosough M. Rhenium Perrhenate (188ReO4) Induced Apoptosis and Reduced Cancerous Phenotype in Liver Cancer Cells. Cells 2022;11:305. [DOI: 10.3390/cells11020305] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
145 Yanhan W, Lianfang L, Hao L, Yunfeng D, Nannan S, Fanfan L, Chengzhan Z, Meilong W, Chuandong S. Effect of Microvascular Invasion on the Prognosis in Hepatocellular Carcinoma and Analysis of Related Risk Factors: A Two-Center Study. Front Surg 2021;8:733343. [PMID: 34869551 DOI: 10.3389/fsurg.2021.733343] [Reference Citation Analysis]
146 Cao X, Cao Z, Shao Y, Liu C, Yan G, Meng X, Zhang L, Chen C, Huang G, Shu H, Lu H. Analysis of Serum Paraoxonase 1 Using Mass Spectrometry and Lectin Immunoassay in Patients With Alpha-Fetoprotein Negative Hepatocellular Carcinoma. Front Oncol 2021;11:651421. [PMID: 33889548 DOI: 10.3389/fonc.2021.651421] [Reference Citation Analysis]
147 Lu J, Zhang X, Zhong B, Lau WY, Madoff DC, Davidson JC, Qi X, Cheng S, Teng G. Management of patients with hepatocellular carcinoma and portal vein tumour thrombosis: comparing east and west. The Lancet Gastroenterology & Hepatology 2019;4:721-30. [DOI: 10.1016/s2468-1253(19)30178-5] [Cited by in Crossref: 46] [Cited by in F6Publishing: 39] [Article Influence: 15.3] [Reference Citation Analysis]
148 Su TS, Li LQ, Liang SX, Xiang BD, Li JX, Ye JZ, Li LQ. A Prospective Study of Liver Regeneration After Radiotherapy Based on a New (Su'S) Target Area Delineation. Front Oncol 2021;11:680303. [PMID: 34513671 DOI: 10.3389/fonc.2021.680303] [Reference Citation Analysis]
149 Li LQ, Liang L, Sun LY, Li C, Wu H, Zhang YM, Zhang WG, Wang H, Zhou YH, Gu WM, Chen TH, Li J, Liang YJ, Xu QR, Diao YK, Jia HD, Wang MD, Zhang CW, Shen F, Huang DS, Yang T. Postoperative morbidity adversely impacts long-term oncologic prognosis following hepatectomy for hepatocellular carcinoma: A multicenter observational study. Eur J Surg Oncol 2021:S0748-7983(21)00455-8. [PMID: 33934940 DOI: 10.1016/j.ejso.2021.04.027] [Reference Citation Analysis]
150 Ding J, Qin Z, Zhou Y, Zhou H, Zhang Q, Wang Y, Jing X, Wang F. Impact of Revision of the LR-M Criteria on the Diagnostic Performance of Contrast-Enhanced Ultrasound LI-RADS. Ultrasound Med Biol 2021;47:3403-10. [PMID: 34598799 DOI: 10.1016/j.ultrasmedbio.2021.08.007] [Reference Citation Analysis]
151 Wen N, Cai Y, Li F, Ye H, Tang W, Song P, Cheng N. The clinical management of hepatocellular carcinoma worldwide: A concise review and comparison of current guidelines: 2022 update. Biosci Trends 2022. [PMID: 35197399 DOI: 10.5582/bst.2022.01061] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
152 Zhang X, Ruan S, Xiao W, Shao J, Tian W, Liu W, Zhang Z, Wan D, Huang J, Huang Q, Yang Y, Yang H, Ding Y, Liang W, Bai X, Liang T. Contrast-enhanced CT radiomics for preoperative evaluation of microvascular invasion in hepatocellular carcinoma: A two-center study.Clin Transl Med. 2020;10:e111. [PMID: 32567245 DOI: 10.1002/ctm2.111] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
153 Chen Y, Pan B, Qiu J, Chen Z, Wang X, Tang N. Increased effects of 2,5-dimethylcelecoxib on sensitivity of hepatocellular carcinoma cells to sorafenib via CYP3A5 expression and activation of AMPK. Toxicol In Vitro 2021;76:105226. [PMID: 34293431 DOI: 10.1016/j.tiv.2021.105226] [Reference Citation Analysis]
154 Chen QF, Li W, Yu SC, Chou YH, Rhim H, Yang X, Shen L, Dong A, Huang T, Huang J, Zhang F, Fan W, Zhao M, Gu Y, Huang Z, Zuo M, Zhai B, Xiao Y, Kuang M, Li J, Han J, Song W, Ma J, Wu P. Consensus of Minimally Invasive and Multidisciplinary Comprehensive Treatment for Hepatocellular Carcinoma - 2020 Guangzhou Recommendations. Front Oncol 2021;11:621834. [PMID: 34277397 DOI: 10.3389/fonc.2021.621834] [Reference Citation Analysis]
155 Wang T, Yang X, Tang H, Kong J, Shen S, Qiu H, Wang W. Integrated nomograms to predict overall survival and recurrence-free survival in patients with combined hepatocellular cholangiocarcinoma (cHCC) after liver resection. Aging (Albany NY) 2020;12:15334-58. [PMID: 32788423 DOI: 10.18632/aging.103577] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
156 Huo YR, Chan MV, Chan C. Resection Plus Post-operative Adjuvant Transcatheter Arterial Chemoembolization (TACE) Compared with Resection Alone for Hepatocellular Carcinoma: A Systematic Review and Meta-analysis. Cardiovasc Intervent Radiol 2020;43:572-86. [PMID: 31897617 DOI: 10.1007/s00270-019-02392-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
157 Chen Z, Cai M, Wang X, Zhou Y, Chen J, Xie Q, Zhao Y, Xie K, Fang Q, Pu T, Jiang D, Bai T, Ma J, Geng X, Liu F. Two novel online nomograms for predicting the survival of individual patients undergoing partial hepatectomy for huge hepatocellular carcinoma. HPB (Oxford) 2021;23:1217-29. [PMID: 33413992 DOI: 10.1016/j.hpb.2020.12.002] [Reference Citation Analysis]
158 Gao Y, Wang PX, Cheng JW, Sun YF, Hu B, Guo W, Zhou KQ, Yin Y, Li YC, Wang J, Huang JF, Qiu SJ, Zhou J, Fan J, Yang XR. Chemotherapeutic perfusion of portal vein after tumor thrombectomy and hepatectomy benefits patients with advanced hepatocellular carcinoma: A propensity score-matched survival analysis. Cancer Med 2019;8:6933-44. [PMID: 31566899 DOI: 10.1002/cam4.2556] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
159 Wei Y, Ye Z, Yuan Y, Huang Z, Wei X, Zhang T, Wan S, Tang H, He X, Song B. A New Diagnostic Criterion with Gadoxetic Acid-Enhanced MRI May Improve the Diagnostic Performance for Hepatocellular Carcinoma. Liver Cancer 2020;9:414-25. [PMID: 32999868 DOI: 10.1159/000505696] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
160 Yang J, Tian Y, Zheng R, Li L, Qiu F. Endocannabinoid system and the expression of endogenous ceramides in human hepatocellular carcinoma. Oncol Lett 2019;18:1530-8. [PMID: 31423220 DOI: 10.3892/ol.2019.10399] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
161 Zeng Z, Cao Z, Tang Y. Identification of diagnostic and prognostic biomarkers, and candidate targeted agents for hepatitis B virus-associated early stage hepatocellular carcinoma based on RNA-sequencing data. Oncol Lett 2020;20:231. [PMID: 32968453 DOI: 10.3892/ol.2020.12094] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
162 Zhang YW, Chen Q, Li B, Li HY, Zhao XK, Xiao YY, Liu S, Zuo S. NAP1L1 Functions as a Tumor Promoter via Recruiting Hepatoma-Derived Growth Factor/c-Jun Signal in Hepatocellular Carcinoma. Front Cell Dev Biol 2021;9:659680. [PMID: 34368121 DOI: 10.3389/fcell.2021.659680] [Reference Citation Analysis]
163 Qin S, Li Q, Gu S, Chen X, Lin L, Wang Z, Xu A, Chen X, Zhou C, Ren Z, Yang L, Xu L, Bai Y, Chen L, Li J, Pan H, Cao B, Fang W, Wu W, Wang G, Cheng Y, Yu Z, Zhu X, Jiang D, Lu Y, Wang H, Xu J, Bai L, Liu Y, Lin H, Wu C, Zhang Y, Yan P, Jin C, Zou J. Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Gastroenterol Hepatol 2021;6:559-68. [PMID: 33971141 DOI: 10.1016/S2468-1253(21)00109-6] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 25.0] [Reference Citation Analysis]
164 Liu W, Zhang L, Xin Z, Zhang H, You L, Bai L, Zhou J, Ying B. A Promising Preoperative Prediction Model for Microvascular Invasion in Hepatocellular Carcinoma Based on an Extreme Gradient Boosting Algorithm. Front Oncol 2022;12:852736. [DOI: 10.3389/fonc.2022.852736] [Reference Citation Analysis]
165 Wang PX, Sun YF, Jin WX, Cheng JW, Peng HX, Xu Y, Zhou KQ, Chen LM, Huang K, Wu SY, Hu B, Zhang ZF, Guo W, Cao Y, Zhou J, Fan J, Yang XR. Circulating tumor cell detection and single-cell analysis using an integrated workflow based on ChimeraX® -i120 Platform: A prospective study. Mol Oncol 2021;15:2345-62. [PMID: 33301640 DOI: 10.1002/1878-0261.12876] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
166 Guo M, Qi F, Rao Q, Sun J, Du X, Qi Z, Yang B, Xia J. Serum LAG-3 Predicts Outcome and Treatment Response in Hepatocellular Carcinoma Patients With Transarterial Chemoembolization. Front Immunol 2021;12:754961. [PMID: 34691076 DOI: 10.3389/fimmu.2021.754961] [Reference Citation Analysis]
167 Zhou Y, Yang Y, Zhou B, Wang Z, Zhu R, Chen X, Ouyang J, Li Q, Zhou J. Challenges Facing Percutaneous Ablation in the Treatment of Hepatocellular Carcinoma: Extension of Ablation Criteria. J Hepatocell Carcinoma 2021;8:625-44. [PMID: 34189133 DOI: 10.2147/JHC.S298709] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
168 Zheng C, Chen L, Jian J, Li J, Gao Z. Efficacy evaluation of interventional therapy for primary liver cancer using magnetic resonance imaging and CT scanning under deep learning and treatment of vasovagal reflex. J Supercomput 2021;77:7535-48. [DOI: 10.1007/s11227-020-03539-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
169 Wang L, Ke Q, Deng M, Huang X, Zeng J, Liu H, Yang Y, Zeng Y, Zhou W, Liu J. Adjuvant transarterial chemoembolization for patients with hepatocellular carcinoma after radical hepatectomy: a real world study. Scand J Gastroenterol 2019;54:1403-11. [PMID: 31686555 DOI: 10.1080/00365521.2019.1684986] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
170 Ji Y, Zhu J, Zhu L, Zhu Y, Zhao H. High-Intensity Focused Ultrasound Ablation for Unresectable Primary and Metastatic Liver Cancer: Real-World Research in a Chinese Tertiary Center With 275 Cases. Front Oncol 2020;10:519164. [PMID: 33194582 DOI: 10.3389/fonc.2020.519164] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
171 Ma J, Li P, Jiang L, Wei H. Long-term outcomes of hepatectomy or radiofrequency ablation associated with splenectomy for treatment of hepatocellular carcinoma and esophagogastric variceal bleeding. Asian Journal of Surgery 2022. [DOI: 10.1016/j.asjsur.2021.11.068] [Reference Citation Analysis]
172 Cai L, Li H, Guo J, Zhao W, Duan Y, Hou X, Cheng L, Du H, Shao X, Diao Z, Li C. Drug-eluting bead transarterial chemoembolization is an effective downstaging option for subsequent radical treatments in patients with hepatocellular carcinoma: A cohort study. Clin Res Hepatol Gastroenterol 2021;45:101535. [PMID: 33121882 DOI: 10.1016/j.clinre.2020.09.002] [Reference Citation Analysis]
173 Sun HX, Yang ZF, Tang WG, Ke AW, Liu WR, Li Y, Gao C, Hu B, Fu PY, Yu MC, Gao BW, Shi YH, Fan J, Xu Y. MicroRNA-19a-3p regulates cell growth through modulation of the PIK3IP1-AKT pathway in hepatocellular carcinoma. J Cancer 2020;11:2476-84. [PMID: 32201518 DOI: 10.7150/jca.37748] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
174 Yang X, Miao BS, Wei CY, Dong RZ, Gao PT, Zhang XY, Lu JC, Gao C, Wang XY, Sun HC, Zhou J, Fan J, Ke AW, Shi GM, Cai JB. Lymphoid-specific helicase promotes the growth and invasion of hepatocellular carcinoma by transcriptional regulation of centromere protein F expression. Cancer Sci 2019;110:2133-44. [PMID: 31066149 DOI: 10.1111/cas.14037] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
175 Spiliotis AE, Gäbelein G, Holländer S, Scherber PR, Glanemann M, Patel B. Microwave ablation compared with radiofrequency ablation for the treatment of liver cancer: a systematic review and meta-analysis. Radiol Oncol 2021;55:247-58. [PMID: 34167181 DOI: 10.2478/raon-2021-0030] [Reference Citation Analysis]
176 Wu J, Liu C, Wang F. Disparities in Hepatocellular Carcinoma Survival by Insurance Status: A Population-Based Study in China. Front Public Health 2021;9:742355. [PMID: 34805067 DOI: 10.3389/fpubh.2021.742355] [Reference Citation Analysis]
177 Wu QJ, Lv WL, Li JM, Zhang TT, Zhou WH, Zhang Q, Wang JC, Wang QN, Yao ZA, Qiang R, Chen ST, Zhao X, Liu S, Cao ZM, Xu L, Li GH, Chen J, Wang L. YinQiSanHuang Jiedu decoction for the treatment of hepatitis B-related compensated liver cirrhosis: study protocol for a multi-center randomized controlled trial. Trials 2021;22:701. [PMID: 34649610 DOI: 10.1186/s13063-021-05650-6] [Reference Citation Analysis]
178 Zhu L, Lin H, Wan S, Chen X, Wu L, Zhu Z, Song Y, Hu B, Yang C. Efficient Isolation and Phenotypic Profiling of Circulating Hepatocellular Carcinoma Cells via a Combinatorial-Antibody-Functionalized Microfluidic Synergetic-Chip. Anal Chem 2020;92:15229-35. [PMID: 33124804 DOI: 10.1021/acs.analchem.0c03936] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
179 Wang PX, Sun YF, Zhou KQ, Cheng JW, Hu B, Guo W, Yin Y, Huang JF, Zhou J, Fan J, Cheung TT, Qu XD, Yang XR. Circulating tumor cells are an indicator for the administration of adjuvant transarterial chemoembolization in hepatocellular carcinoma: A single-center, retrospective, propensity-matched study.Clin Transl Med. 2020;10:e137. [PMID: 32702202 DOI: 10.1002/ctm2.137] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
180 Qiu Y, Wang T, Yang X, Shen S, Yang Y, Wang W. Development and Validation of Artificial Neural Networks for Survival Prediction Model for Patients with Spontaneous Hepatocellular Carcinoma Rupture After Transcatheter Arterial Embolization. Cancer Manag Res 2021;13:7463-77. [PMID: 34611440 DOI: 10.2147/CMAR.S328307] [Reference Citation Analysis]
181 Lu J, Zhao M, Arai Y, Zhong BY, Zhu HD, Qi XL, de Baere T, Pua U, Yoon HK, Madoff DC, Teng GJ; International Society of Multidisciplinary Interventional Oncology (ISMIO). Clinical practice of transarterial chemoembolization for hepatocellular carcinoma: consensus statement from an international expert panel of International Society of Multidisciplinary Interventional Oncology (ISMIO). Hepatobiliary Surg Nutr 2021;10:661-71. [PMID: 34760969 DOI: 10.21037/hbsn-21-260] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
182 Deng S, Jiang Q, Wang Y, Lu X, Zhang Y. Relationship between quantitative contrast-enhanced ultrasonography parameters and angiogenesis in primary small hepatocellular carcinoma: A retrospective study. Medicine (Baltimore) 2021;100:e26489. [PMID: 34232180 DOI: 10.1097/MD.0000000000026489] [Reference Citation Analysis]
183 Wang L, Ke Q, Lin K, Chen J, Wang R, Xiao C, Liu X, Liu J. Not All Hepatocellular Carcinoma Patients with Microvascular Invasion After R0 Resection Could Be Benefited from Prophylactic Transarterial Chemoembolization: A Propensity Score Matching Study. Cancer Manag Res 2020;12:3815-25. [PMID: 32547217 DOI: 10.2147/CMAR.S251605] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
184 Erridge S, Sodergren MH. The Chengdu system for recurrent hepatocellular carcinoma: A step in the right direction.Hepatobiliary Surg Nutr. 2019;8:298-300. [PMID: 31245419 DOI: 10.21037/hbsn.2019.01.17] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
185 Zhu XD, Huang C, Shen YH, Ji Y, Ge NL, Qu XD, Chen L, Shi WK, Li ML, Zhu JJ, Tan CJ, Tang ZY, Zhou J, Fan J, Sun HC. Downstaging and Resection of Initially Unresectable Hepatocellular Carcinoma with Tyrosine Kinase Inhibitor and Anti-PD-1 Antibody Combinations. Liver Cancer 2021;10:320-9. [PMID: 34414120 DOI: 10.1159/000514313] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
186 Yu L, Liu X, Wang X, Dang Z, Jiang Y, Wang X, Yang Z. Impact of gender as a prognostic factor in HBV-related Hepatocellular Carcinoma: the survival strength of female patients in BCLC stage 0-B. J Cancer 2019;10:4237-44. [PMID: 31413742 DOI: 10.7150/jca.33430] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
187 Liu S, Wang R, Lou Y, Liu J. Uncovering the Mechanism of the Effects of Pien-Tze-Huang on Liver Cancer Using Network Pharmacology and Molecular Docking. Evid Based Complement Alternat Med 2020;2020:4863015. [PMID: 32963562 DOI: 10.1155/2020/4863015] [Reference Citation Analysis]
188 Rim CH, Cheng J, Huang W, Kimura T, Lee V, Zeng Z, Seong J. An evaluation of hepatocellular carcinoma practice guidelines from a radiation oncology perspective. Radiotherapy and Oncology 2020;148:73-81. [DOI: 10.1016/j.radonc.2020.03.027] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 4.5] [Reference Citation Analysis]
189 Wang Y, Xiao X, Chen S, Huang C, Zhou J, Dai E, Li Y, Liu L, Huang X, Gao Z, Wu C, Fang M, Gao C. The Impact of HBV Quasispecies Features on Immune Status in HBsAg+/HBsAb+ Patients With HBV Genotype C Using Next-Generation Sequencing. Front Immunol 2021;12:775461. [PMID: 34899733 DOI: 10.3389/fimmu.2021.775461] [Reference Citation Analysis]
190 Masuda S, Tsukiyama T, Minagawa Y, Koizumi K, Kako M, Kinbara T, Haruki U. Hepatocellular carcinoma effective stereotactic body radiotherapy using Gold Anchor and the Synchrony system: Two case reports and review of literature. World J Clin Cases 2022; 10(8): 2591-2603 [DOI: 10.12998/wjcc.v10.i8.2591] [Reference Citation Analysis]
191 Zhu XX, Li JH, Cai JP, Hou X, Huang CS, Huang XT, Wang JQ, Li SJ, Xu QC, Yin XY. EYA4 inhibits hepatocellular carcinoma by repressing MYCBP by dephosphorylating β-catenin at Ser552. Cancer Sci 2019;110:3110-21. [PMID: 31385398 DOI: 10.1111/cas.14159] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
192 Jiang Z, Wang S, Jin J, Ying S, Chen Z, Zhu D, Xiao B, Hu Y, Qian Y, Cai T, Fu L. The clinical significance of serum chitinase 3-like 1 in hepatitis B-related chronic liver diseases. J Clin Lab Anal 2020;34:e23200. [PMID: 31916309 DOI: 10.1002/jcla.23200] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
193 Ye Z, Deng Z, Jiang S, Wang T, Liu L, Jiang K, Zhang Y. Radiologic Response Combined with Dermatologic Toxicities is the Most Robust Predictor of Survival Benefits in Patients with Inoperable Hepatocellular Carcinoma After Transarterial Chemoembolization Plus Sorafenib Therapy. Cardiovasc Intervent Radiol 2021;44:1394-402. [PMID: 33948697 DOI: 10.1007/s00270-021-02846-w] [Reference Citation Analysis]
194 Liao R, Wei X, Che P, Yin K, Liu L. Nomograms Incorporating the CNLC Staging System Predict the Outcome of Hepatocellular Carcinoma After Curative Resection. Front Oncol 2022;11:755920. [DOI: 10.3389/fonc.2021.755920] [Reference Citation Analysis]
195 Wu G, Wu J, Pan X, Liu B, Yao Z, Guo Y, Shi X, Ding Y. Racial disparities in alpha-fetoprotein testing and alpha-fetoprotein status associated with the diagnosis and outcome of hepatocellular carcinoma patients. Cancer Med. 2019;8:6614-6623. [PMID: 31517445 DOI: 10.1002/cam4.2549] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
196 Sun M, Shang P, Bai J, Li S, Li M. High-intensity focused ultrasound ablation combined with transcatheter arterial chemoembolization improves long-term efficacy and prognosis of primary liver cancer. J Clin Lab Anal 2021;35:e23633. [PMID: 33099812 DOI: 10.1002/jcla.23633] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
197 Liu LL, Zhang SW, Chao X, Wang CH, Yang X, Zhang XK, Wen YL, Yun JP, Luo RZ. Coexpression of CMTM6 and PD-L1 as a predictor of poor prognosis in macrotrabecular-massive hepatocellular carcinoma. Cancer Immunol Immunother. 2021;70:417-429. [PMID: 32770259 DOI: 10.1007/s00262-020-02691-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
198 Fu PY, Hu B, Ma XL, Tang WG, Yang ZF, Sun HX, Yu MC, Huang A, Hu JW, Zhou CH, Fan J, Xu Y, Zhou J. Far upstream element-binding protein 1 facilitates hepatocellular carcinoma invasion and metastasis. Carcinogenesis 2020;41:950-60. [PMID: 31587040 DOI: 10.1093/carcin/bgz171] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
199 Tian MX, Liu WR, Wang H, Zhou YF, Jin L, Jiang XF, Tao CY, Tang Z, Zhou PY, Fang Y, Qu WF, Ding ZB, Peng YF, Dai Z, Qiu SJ, Zhou J, Lau WY, Fan J, Shi YH. Tissue-infiltrating lymphocytes signature predicts survival in patients with early/intermediate stage hepatocellular carcinoma. BMC Med 2019;17:106. [PMID: 31164128 DOI: 10.1186/s12916-019-1341-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
200 Zheng J, Cai J, Tao L, Kirih MA, Shen Z, Xu J, Liang X. Comparison on the efficacy and prognosis of different strategies for intrahepatic recurrent hepatocellular carcinoma: A systematic review and Bayesian network meta-analysis. International Journal of Surgery 2020;83:196-204. [DOI: 10.1016/j.ijsu.2020.09.031] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
201 Hu B, Xu Y, Li YC, Huang JF, Cheng JW, Guo W, Yin Y, Gao Y, Wang PX, Wu SY, Zhou J, Fan J, Yang XR. CD13 promotes hepatocellular carcinogenesis and sorafenib resistance by activating HDAC5-LSD1-NF-κB oncogenic signaling. Clin Transl Med 2020;10:e233. [PMID: 33377659 DOI: 10.1002/ctm2.233] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
202 Liu WR, Tian MX, Tang Z, Fang Y, Zhou YF, Song SS, Jiang XF, Wang H, Tao CY, Zhou PY, Qu WF, Ding ZB, Peng YF, Zhou J, Fan J, Shi YH. Nine-factor-based immunohistochemistry classifier predicts recurrence for early-stage hepatocellular carcinoma after curative resection. Br J Cancer 2020;123:92-100. [PMID: 32376890 DOI: 10.1038/s41416-020-0864-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
203 Song D, Wang Y, Zhu K, Tian L, Gao Q, Zhou J, Fan J, Wang X. DCK is a promising prognostic biomarker and correlated with immune infiltrates in hepatocellular carcinoma. World J Surg Oncol 2020;18:176. [PMID: 32690026 DOI: 10.1186/s12957-020-01953-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
204 Cheng AL, Hsu C, Chan SL, Choo SP, Kudo M. Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma. J Hepatol. 2020;72:307-319. [PMID: 31954494 DOI: 10.1016/j.jhep.2019.09.025] [Cited by in Crossref: 69] [Cited by in F6Publishing: 75] [Article Influence: 69.0] [Reference Citation Analysis]
205 Xu YP, Dong ZN, Wang SW, Zheng YM, Zhang C, Zhou YQ, Zhao YJ, Zhao Y, Wang F, Peng R, Tang MC, Bai DS, Huang XY, Guo CY. circHMGCS1-016 reshapes immune environment by sponging miR-1236-3p to regulate CD73 and GAL-8 expression in intrahepatic cholangiocarcinoma. J Exp Clin Cancer Res 2021;40:290. [PMID: 34526098 DOI: 10.1186/s13046-021-02095-2] [Reference Citation Analysis]
206 Chen L, Yu CX, Zhong BY, Zhu HD, Jin ZC, Zhu GY, Zhang Q, Ni CF, Teng GJ. Development of TACE Refractoriness Scores in Hepatocellular Carcinoma. Front Mol Biosci 2021;8:615133. [PMID: 33981722 DOI: 10.3389/fmolb.2021.615133] [Reference Citation Analysis]
207 Schoenberg MB, Li X, Li X, Han Y, Börner N, Koch D, Guba MO, Werner J, Bazhin AV. The interactions between major immune effector cells and Hepatocellular Carcinoma: A systematic review. Int Immunopharmacol 2021;101:108220. [PMID: 34673334 DOI: 10.1016/j.intimp.2021.108220] [Reference Citation Analysis]
208 Liu F, Luo L, Liu Z, Wu S, Zhang W, Li Q, Peng Y, Wei Y, Li B. A genetic variant in the promoter of CD46 is associated with the risk and prognosis of hepatocellular carcinoma. Mol Carcinog 2020;59:1243-55. [PMID: 32869896 DOI: 10.1002/mc.23252] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
209 Li S, Lyu N, Han X, Li J, Lai J, He M, Deng H, Shi M, Wang H, Zhao M. Hepatic Artery Infusion Chemotherapy Using Fluorouracil, Leucovorin, and Oxaliplatin versus Transarterial Chemoembolization as Initial Treatment for Locally Advanced Hepatocellular Carcinoma: A Propensity Score-Matching Analysis. J Vasc Interv Radiol 2021;32:1267-1276.e1. [PMID: 34166806 DOI: 10.1016/j.jvir.2021.06.008] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
210 Lin XN, Lin QX, Li SM, Xie KP, Hou J, Chen R. Hepatitis E virus re-infection accelerates hepatocellular carcinoma development and relapse in a patient with liver cirrhosis: A case report and review of literature. World J Hepatol 2020; 12(12): 1358-1366 [PMID: 33442461 DOI: 10.4254/wjh.v12.i12.1358] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
211 Kong WS, Shen FX, Xie RF, Zhou G, Feng YM, Zhou X. Bufothionine induces autophagy in H22 hepatoma-bearing mice by inhibiting JAK2/STAT3 pathway, a possible anti-cancer mechanism of cinobufacini. J Ethnopharmacol 2021;270:113848. [PMID: 33485977 DOI: 10.1016/j.jep.2021.113848] [Reference Citation Analysis]
212 Yao SY, Liang B, Chen YY, Tang YT, Dong XF, Liu TQ. Clinical stages of recurrent hepatocellular carcinoma: A retrospective cohort study. World J Clin Cases 2021; 9(27): 8020-8026 [PMID: 34621858 DOI: 10.12998/wjcc.v9.i27.8020] [Reference Citation Analysis]
213 Xiao X, Zhou L, Zhang L, Xu Z, Dai Q, Deng X, Li W. Short-Term and Long-Term Curative Effect of Partial Hepatectomy on Ruptured Hemorrhage of Primary Liver Cancer after TAE. Emergency Medicine International 2022;2022:1-7. [DOI: 10.1155/2022/2484418] [Reference Citation Analysis]
214 Qin S, Ren Z, Feng YH, Yau T, Wang B, Zhao H, Bai Y, Gu S, Li L, Hernandez S, Xu DZ, Mulla S, Wang Y, Shao H, Cheng AL. Atezolizumab plus Bevacizumab versus Sorafenib in the Chinese Subpopulation with Unresectable Hepatocellular Carcinoma: Phase 3 Randomized, Open-Label IMbrave150 Study. Liver Cancer 2021;10:296-308. [PMID: 34414118 DOI: 10.1159/000513486] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
215 Jonas E, Bernon M, Robertson B, Kassianides C, Keli E, Asare KO, Alatise IO, Okello M, Blondel NO, Mulehane KO, Abubeker ZA, Nogoud AA, Nashidengo PR, Chihaka O, Tzeuton C, Dusheiko G, Sonderup M, Spearman CW. Treatment of hepatocellular carcinoma in sub-Saharan Africa: challenges and solutions. The Lancet Gastroenterology & Hepatology 2022. [DOI: 10.1016/s2468-1253(22)00042-5] [Reference Citation Analysis]
216 Vitale A, Farinati F, Finotti M, Di Renzo C, Brancaccio G, Piscaglia F, Cabibbo G, Caturelli E, Missale G, Marra F, Sacco R, Giannini EG, Trevisani F, Cillo U, Associazione Italiana Per Lo Studio Del Fegato Aisf Hcc Special Interest Group, Italian Liver Cancer Ita Li Ca Study Group. Overview of Prognostic Systems for Hepatocellular Carcinoma and ITA.LI.CA External Validation of MESH and CNLC Classifications. Cancers (Basel) 2021;13:1673. [PMID: 33918125 DOI: 10.3390/cancers13071673] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
217 Zhu YF, Tan YF, Xu X, Zheng JL, Zhang BH, Tang HR, Yang JY. Gamma-glutamyl transpeptidase-to-platelet ratio and the fibrosis-4 index in predicting hepatitis B virus-related hepatocellular carcinoma development in elderly chronic hepatitis B patients in China: A single-center retrospective study. Medicine (Baltimore) 2019;98:e18319. [PMID: 31852119 DOI: 10.1097/MD.0000000000018319] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
218 Dong L, Lu D, Chen R, Lin Y, Zhu H, Zhang Z, Cai S, Cui P, Song G, Rao D, Yi X, Wu Y, Song N, Liu F, Zou Y, Zhang S, Zhang X, Wang X, Qiu S, Zhou J, Wang S, Zhang X, Shi Y, Figeys D, Ding L, Wang P, Zhang B, Rodriguez H, Gao Q, Gao D, Zhou H, Fan J. Proteogenomic characterization identifies clinically relevant subgroups of intrahepatic cholangiocarcinoma. Cancer Cell 2021:S1535-6108(21)00659-0. [PMID: 34971568 DOI: 10.1016/j.ccell.2021.12.006] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 17.0] [Reference Citation Analysis]
219 Chen YX, Zhuang Y, Yang P, Fan J, Zhou J, Hu Y, Zhu WC, Sun J, Zeng ZC. Helical IMRT-Based Stereotactic Body Radiation Therapy Using an Abdominal Compression Technique and Modified Fractionation Regimen for Small Hepatocellular Carcinoma. Technol Cancer Res Treat 2020;19:1533033820937002. [PMID: 32613904 DOI: 10.1177/1533033820937002] [Reference Citation Analysis]
220 Lin N, Li J, Ke Q, Wang L, Cao Y, Liu J. Clinical Significance of C-Reactive Protein to Albumin Ratio in Patients with Hepatocellular Carcinoma: A Meta-Analysis.Dis Markers. 2020;2020:4867974. [PMID: 32963635 DOI: 10.1155/2020/4867974] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
221 Zhang S, Liu Y, Chen J, Shu H, Shen S, Li Y, Lu X, Cao X, Dong L, Shi J, Cao Y, Wang X, Zhou J, Liu Y, Chen L, Fan J, Ding G, Gao Q. Autoantibody signature in hepatocellular carcinoma using seromics. J Hematol Oncol 2020;13:85. [PMID: 32616055 DOI: 10.1186/s13045-020-00918-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
222 Zhao L, Teng L, Zhang W, Lin S, Liu X, Dai J, Shao H, Li X, Liu Q, Zou H. Dose of intra-operative opioids has no impact on recurrence or survival in primary liver cancer. Cancer Med 2022. [PMID: 35588234 DOI: 10.1002/cam4.4827] [Reference Citation Analysis]
223 Gao Y, Lyu L, Feng Y, Li F, Hu Y. A review of cutting-edge therapies for hepatocellular carcinoma (HCC): Perspectives from patents. Int J Med Sci 2021;18:3066-81. [PMID: 34400877 DOI: 10.7150/ijms.59930] [Reference Citation Analysis]
224 Peng W, Yao M, Zou K, Li C, Wen T, Sun X. Postoperative controlling nutritional status score is an independent risk factor of survival for patients with small hepatocellular carcinoma: a retrospective study. BMC Surg 2021;21:338. [PMID: 34493254 DOI: 10.1186/s12893-021-01334-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
225 Zhou TY, Chen SQ, Wang HL, Weng SM, Zhou GH, Zhang YL, Nie CH, Zhu TY, Wang BQ, Yu ZN, Jing L, Chen F, Sun JH. Safety and efficacy of drug-eluting bead transarterial chemoembolization with CalliSpheres® microsphere for hepatocellular carcinoma with portal vein tumor thrombus: a preliminary study. J Cancer 2021;12:4522-9. [PMID: 34149916 DOI: 10.7150/jca.54650] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
226 Xu XY, Ding HG, Li WG, Xu JH, Han Y, Jia JD, Wei L, Duan ZP, Ling-Hu EQ, Zhuang H. Chinese guidelines on the management of liver cirrhosis (abbreviated version) . World J Gastroenterol 2020; 26(45): 7088-7103 [PMID: 33362370 DOI: 10.3748/wjg.v26.i45.7088] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
227 Zhang HG, Yang P, Jiang T, Zhang JY, Jin XJ, Hu Y, Sun J, Du SS, Zeng ZC. Lymphopenia Is Associated with Gross Target Volumes and Fractions in Hepatocellular Carcinoma Patients Treated with External Beam Radiation Therapy and Also Indicates Worse Overall Survival. Can J Gastroenterol Hepatol 2019;2019:9691067. [PMID: 31781521 DOI: 10.1155/2019/9691067] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
228 Xie DY, Ren ZG, Zhou J, Fan J, Gao Q. 2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: updates and insights. Hepatobiliary Surg Nutr. 2020;9:452-463. [PMID: 32832496 DOI: 10.21037/hbsn-20-480] [Cited by in Crossref: 26] [Cited by in F6Publishing: 33] [Article Influence: 13.0] [Reference Citation Analysis]
229 Wang K, Li M, Qin J, Sun G, Dai L, Wang P, Ye H, Shi J, Cheng L, Yang Q, Qiu C, Jiang D, Wang X, Zhang J. Serological Biomarkers for Early Detection of Hepatocellular Carcinoma: A Focus on Autoantibodies against Tumor-Associated Antigens Encoded by Cancer Driver Genes. Cancers (Basel) 2020;12:E1271. [PMID: 32443439 DOI: 10.3390/cancers12051271] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
230 Yu L, Liu X, Jiang Y, Wang X, Wang X, Yang Z. Use of a Novel Thyroid-Stimulating Hormone Model for Predicting the Progression of Hepatocellular Carcinoma. Onco Targets Ther 2020;13:11421-31. [PMID: 33192075 DOI: 10.2147/OTT.S275304] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
231 Chen LC, Lin HY, Hung SK, Chiou WY, Lee MS. Role of modern radiotherapy in managing patients with hepatocellular carcinoma. World J Gastroenterol 2021; 27(20): 2434-2457 [PMID: 34092968 DOI: 10.3748/wjg.v27.i20.2434] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
232 Wang Y, Zhong J, Xu H, Xu G, Wang L, Xu D, Wang H, Wang K, Xiang B, Mao Y, Li L, Xing B. A modified staging of early and intermediate hepatocellular carcinoma based on single tumour >7 cm and multiple tumours beyond up-to-seven criteria. Aliment Pharmacol Ther 2019;49:202-10. [DOI: 10.1111/apt.15074] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
233 Yang X, Cai JB, Peng R, Wei CY, Lu JC, Gao C, Shen ZZ, Zhang PF, Huang XY, Ke AW, Shi GM, Fan J. The long noncoding RNA NORAD enhances the TGF-β pathway to promote hepatocellular carcinoma progression by targeting miR-202-5p. J Cell Physiol 2019;234:12051-60. [PMID: 30537113 DOI: 10.1002/jcp.27869] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
234 Liang B, Makamure J, Shu S, Zhang L, Sun T, Zheng C. Treatment Response, Survival, and Safety of Transarterial Chemoembolization With CalliSpheres® Microspheres Versus Conventional Transarterial Chemoembolization in Hepatocellular Carcinoma: A Meta-Analysis. Front Oncol 2021;11:576232. [PMID: 33796448 DOI: 10.3389/fonc.2021.576232] [Reference Citation Analysis]
235 Zhou H, Jiang T, Li Q, Zhang C, Zhang C, Liu Y, Cao J, Sun Y, Jin P, Luo J, Pan M, Huang P. US-Based Deep Learning Model for Differentiating Hepatocellular Carcinoma (HCC) From Other Malignancy in Cirrhotic Patients. Front Oncol 2021;11:672055. [PMID: 34168992 DOI: 10.3389/fonc.2021.672055] [Reference Citation Analysis]
236 Chen S, Li H, Lin X, Hu S, Zhang Z. Development and Evaluation of Nutrition Screening Tool in Patients with Hepatitis B-Related Cirrhosis: A Cross-Sectional Study. Risk Manag Healthc Policy 2021;14:1823-31. [PMID: 33986619 DOI: 10.2147/RMHP.S299428] [Reference Citation Analysis]
237 Fan PL, Ding H, Mao F, Chen LL, Dong Y, Wang WP. Enhancement patterns of small hepatocellular carcinoma (≤ 30 mm) on contrast-enhanced ultrasound: Correlation with clinicopathologic characteristics. Eur J Radiol 2020;132:109341. [PMID: 33069987 DOI: 10.1016/j.ejrad.2020.109341] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
238 Lin J, Zhao H. Systemic management for patients with hepatobiliary tumors in a multi-dimensional view. Hepatobiliary Surg Nutr 2019;8:626-8. [PMID: 31929990 DOI: 10.21037/hbsn.2019.07.21] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
239 Najafi S, Khatami SH, Khorsand M, Jamali Z, Shabaninejad Z, Moazamfard M, Majidpoor J, Aghaei Zarch SM, Movahedpour A. Long non-coding RNAs (lncRNAs); roles in tumorigenesis and potentials as biomarkers in cancer diagnosis. Exp Cell Res 2022;:113294. [PMID: 35870535 DOI: 10.1016/j.yexcr.2022.113294] [Reference Citation Analysis]
240 Luo X, Zheng E, Wei L, Zeng H, Qin H, Zhang X, Liao M, Chen L, Zhao L, Ruan XZ, Yang P, Chen Y. The fatty acid receptor CD36 promotes HCC progression through activating Src/PI3K/AKT axis-dependent aerobic glycolysis. Cell Death Dis 2021;12:328. [PMID: 33771982 DOI: 10.1038/s41419-021-03596-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
241 Chen S, Zhang K, Liu W, Yu W. Hepatic arterial infusion of oxaliplatin plus raltitrexed in patients with intermediate and advanced stage hepatocellular carcinoma: A phase II, single-arm, prospective study. Eur J Cancer 2020;134:90-8. [PMID: 32497895 DOI: 10.1016/j.ejca.2020.03.032] [Reference Citation Analysis]
242 Yu T, Ye X, Wen Z, Zhu G, Su H, Han C, Huang K, Qin W, Liao X, Yang C, Liu Z, Wang X, Xu B, Su M, Lv Z, Lau WY, Peng T. Intraoperative Indocyanine Green Retention Test of Left Hemiliver in Decision-Making for Patients With Hepatocellular Carcinoma Undergoing Right Hepatectomy. Front Surg 2021;8:709017. [PMID: 34604294 DOI: 10.3389/fsurg.2021.709017] [Reference Citation Analysis]
243 Yu CX, Chen YS, Ge ZJ, Zhang YH, Xu X, Tian T, Wen Y, Zhu J, Song C, Chen JG, Hu ZB. Dietary habits and risk of hepatocellular carcinoma among hepatitis B surface antigen carriers: A prospective cohort study in China. J Dig Dis 2020;21:406-15. [PMID: 32407579 DOI: 10.1111/1751-2980.12878] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
244 Rim CH, Lee HY, Kim JS, Kim H. Radiofrequency ablation and stereotactic body radiotherapy for hepatocellular carcinoma: should they clash or reconcile? Int J Radiat Biol 2021;97:111-9. [PMID: 33253598 DOI: 10.1080/09553002.2021.1857453] [Reference Citation Analysis]
245 Ju S, Wang W, Chen P, Li F, Li H, Wang M, Han X, Ren J, Duan X. Drug-eluting bead transarterial chemoembolization followed by apatinib is effective and safe in treating hepatocellular carcinoma patients with BCLC stage C. Clin Res Hepatol Gastroenterol 2022;:101859. [PMID: 34999249 DOI: 10.1016/j.clinre.2022.101859] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
246 Lu LL, Zhang YH, Yao MH, Lu JH, Chen YS, Xu J, Zhu J, Chen HZ, Chen JG. ABO blood groups and liver cancer: prospective results from an HBsAg cohort study. BMJ Open 2021;11:e044039. [PMID: 33980521 DOI: 10.1136/bmjopen-2020-044039] [Reference Citation Analysis]
247 Ding HF, Zhang XF, Bagante F, Ratti F, Marques HP, Soubrane O, Lam V, Poultsides GA, Popescu I, Alexandrescu S, Martel G, Workneh A, Guglielmi A, Hugh T, Aldrighetti L, Lv Y, Pawlik TM. Prediction of tumor recurrence by α-fetoprotein model after curative resection for hepatocellular carcinoma. Eur J Surg Oncol 2021;47:660-6. [PMID: 33082065 DOI: 10.1016/j.ejso.2020.10.017] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
248 You R, Xu Q, Wang Q, Zhang Q, Zhou W, Cao C, Huang X, Ji H, Lv P, Jiang H, Lu Y, Jin Y, Li Y, Cheng L, Wang W, Xu H, Zhu X, Yin G. Efficacy and safety of camrelizumab plus transarterial chemoembolization in intermediate to advanced hepatocellular carcinoma patients: A prospective, multi-center, real-world study. Front Oncol 2022;12:816198. [DOI: 10.3389/fonc.2022.816198] [Reference Citation Analysis]
249 Chen S, Yu W, Zhang K, Liu W, Chen C. Comparison of the efficacy and safety of conventional transarterial chemoembolization with and without drug-eluting beads embolization for the treatment of unresectable large hepatocellular carcinoma. Hepatol Res 2021;51:482-9. [PMID: 33462925 DOI: 10.1111/hepr.13620] [Reference Citation Analysis]
250 Huang G, Li L, Liang C, Yu F, Teng C, Pang Y, Wei T, Song J, Wang H, Liao X, Li Y, Yang J. Upregulated UCA1 contributes to oxaliplatin resistance of hepatocellular carcinoma through inhibition of miR-138-5p and activation of AKT/mTOR signaling pathway. Pharmacol Res Perspect 2021;9:e00720. [PMID: 33565716 DOI: 10.1002/prp2.720] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
251 Zhou Y, Zhou X, Ma J, Zhang W, Yan Z, Luo J. Nomogram for Predicting the Prognosis of Patients with Hepatocellular Carcinoma Presenting with Pulmonary Metastasis. Cancer Manag Res 2021;13:2083-94. [PMID: 33688251 DOI: 10.2147/CMAR.S296020] [Reference Citation Analysis]
252 Wei B, Chen H, Chen X, Guo D, Hong L, Zheng S. Sox15 Methylation Inhibits Cell Proliferation Through Wnt Signaling in Hepatocellular Carcinoma. Front Oncol 2022;12:842312. [PMID: 35392235 DOI: 10.3389/fonc.2022.842312] [Reference Citation Analysis]
253 Liu J, Li Q, Shi N, Chen Y, Li Y, Zhang M, Huang Y. Preliminary clinical study of the safety of hepatectomy predicted by gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced T1 mapping magnetic resonance imaging. JGH Open 2021;5:382-9. [PMID: 33732886 DOI: 10.1002/jgh3.12507] [Reference Citation Analysis]
254 Dong K, Liang B, Zhang Z, Zhang E, Yang G, Xia S, Chen X, Huang Z. Histologic severity of liver cirrhosis: A key factor affecting surgical outcomes of hepatocellular carcinoma in patients with portal hypertension. Asian Journal of Surgery 2019;42:981-9. [DOI: 10.1016/j.asjsur.2019.01.009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
255 Liu H, Yang Y, Chen C, Wang L, Huang Q, Zeng J, Lin K, Zeng Y, Guo P, Zhou W, Liu J. Reclassification of tumor size for solitary HBV-related hepatocellular carcinoma by minimum p value method: a large retrospective study. World J Surg Oncol. 2020;18:185. [PMID: 32709254 DOI: 10.1186/s12957-020-01963-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
256 Li LQ, Zhou Y, Huang Y, Liang P, Liang SX, Su TS. Stereotactic body radiotherapy versus intensity-modulated radiotherapy for hepatocellular carcinoma with portal vein tumor thrombosis. Hepatol Int 2021;15:630-41. [PMID: 33818714 DOI: 10.1007/s12072-021-10173-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 10.0] [Reference Citation Analysis]
257 Wang W, Li Q, Huang G, Lin BY, Lin D, Ma Y, Zhang Z, Chen T, Zhou J. Tandem Mass Tag-Based Proteomic Analysis of Potential Biomarkers for Hepatocellular Carcinoma Differentiation. Onco Targets Ther 2021;14:1007-20. [PMID: 33603407 DOI: 10.2147/OTT.S273823] [Reference Citation Analysis]
258 Zhuang Y, Yuan BY, Hu Y, Chen GW, Zhang L, Zhao XM, Chen YX, Zeng ZC. Pre/Post-Treatment Dynamic of Inflammatory Markers Has Prognostic Value in Patients with Small Hepatocellular Carcinoma Managed by Stereotactic Body Radiation Therapy. Cancer Manag Res 2019;11:10929-37. [PMID: 32099457 DOI: 10.2147/CMAR.S231901] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
259 Su TS, Liang P, Zhou Y, Huang Y, Cheng T, Qu S, Chen L, Xiang BD, Zhao C, Huang DJ, Liang SX, Li LQ. Stereotactic Body Radiation Therapy vs. Transarterial Chemoembolization in Inoperable Barcelona Clinic Liver Cancer Stage a Hepatocellular Carcinoma: A Retrospective, Propensity-Matched Analysis. Front Oncol 2020;10:347. [PMID: 32266136 DOI: 10.3389/fonc.2020.00347] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
260 Huang XY, Zhang PF, Wei CY, Peng R, Lu JC, Gao C, Cai JB, Yang X, Fan J, Ke AW, Zhou J, Shi GM. Circular RNA circMET drives immunosuppression and anti-PD1 therapy resistance in hepatocellular carcinoma via the miR-30-5p/snail/DPP4 axis. Mol Cancer 2020;19:92. [PMID: 32430013 DOI: 10.1186/s12943-020-01213-6] [Cited by in Crossref: 19] [Cited by in F6Publishing: 27] [Article Influence: 9.5] [Reference Citation Analysis]
261 Zeng Z, Cao Z, Zhang E, Huang H, Tang Y. Elevated CDK5R1 predicts worse prognosis in hepatocellular carcinoma based on TCGA data. Biosci Rep 2021;41:BSR20203594. [PMID: 33346796 DOI: 10.1042/BSR20203594] [Reference Citation Analysis]
262 Huang A, Yang XR, Chung WY, Dennison AR, Zhou J. Targeted therapy for hepatocellular carcinoma. Signal Transduct Target Ther 2020;5:146. [PMID: 32782275 DOI: 10.1038/s41392-020-00264-x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 28] [Article Influence: 11.5] [Reference Citation Analysis]
263 Wang J, Huang A, Wang YP, Yin Y, Fu PY, Zhang X, Zhou J. Circulating tumor DNA correlates with microvascular invasion and predicts tumor recurrence of hepatocellular carcinoma. Ann Transl Med 2020;8:237. [PMID: 32309384 DOI: 10.21037/atm.2019.12.154] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
264 Li HT, Wei B, Li ZQ, Wang X, Jia WX, Xu YZ, Liu JY, Shao MN, Chen SX, Mo NF, Zhao D, Zuo WP, Qin J, Li P, Zhang QL, Yang XL. Diagnostic and prognostic value of MCM3 and its interacting proteins in hepatocellular carcinoma. Oncol Lett 2020;20:308. [PMID: 33093917 DOI: 10.3892/ol.2020.12171] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]